

1 **Clinical Practice Guideline: Lymphedema**  
 2  
 3 **Date of Implementation:                   October 18, 2012**  
 4  
 5 **Effective Date:                               May 21, 2026**  
 6  
 7 **Product:                                       Specialty**

---

8 *Table of Contents*

9 GUIDELINES ..... 1  
 10 DESCRIPTION ..... 3  
 11     Duration and Frequency ..... 4  
 12     Contraindications..... 4  
 13 GENERAL BACKGROUND ..... 4  
 14 EVIDENCE REVIEW..... 6  
 15     Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD), and Compression  
 16     Methods ..... 6  
 17     Other Treatments .....22  
 18         Low Level Laser Therapy (LLLT) .....22  
 19         Exercise .....24  
 20         Measurement of Lymphedema .....32  
 21 PRACTITIONER SCOPE AND TRAINING .....32  
 22 References .....33

23  
 24 **GUIDELINES**

25 **Medically Necessary**

26 American Specialty Health – Specialty (ASH) considers complex lymphedema therapy  
 27 (complete decongestive therapy) medically necessary for the treatment of intractable  
 28 lymphedema when **ALL of the following** are met:

- 29     • Documented failure of a reasonable course of conservative medical management  
 30     that includes home exercises, limb elevation, and compression garments.  
 31     • The lymphedema is directly responsible for impaired functioning in the affected  
 32     limb.  
 33     • The complex lymphedema therapy is prescribed by or under the supervision of an  
 34     appropriate healthcare provider.

**Not Medically Necessary**

Vasopneumatic compression device use as part of complex lymphedema therapy is considered not medically necessary.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

**CPT® Codes and Descriptions**

<b>CPT® Code</b>	<b>CPT® Code Description</b>
97140	Manual therapy techniques (e.g., mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
97535	Self-care/home management training (e.g., activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes
29581	Application of multi-layer compression system; leg (below knee), including ankle and foot
29584	Application of multi-layer compression system; upper arm, forearm, hand, and fingers

**HCPCS Codes and Descriptions**

<b>HCPCS Code</b>	<b>HCPCS Code Description</b>
S8430	Padding for compression bandage, roll
S8431	Compression bandage, roll
S8950	Complex lymphedema therapy, each 15 minutes

Multi-layered, sustained, graduated, high compression bandage systems (CPT® code 29581- Application of multi-layer compression system; leg (below knee), including ankle and foot and CPT® code 29584 - Application of multi-layer compression system; upper arm, forearm, hand, and fingers) are used primarily to treat lymphedema and venous or stasis ulcers. A number of graduated, high-compression bandage systems products have been developed, including Profore®, Dyna-Flex®, Surepress®, Setopress®, and other similar product systems.

1 Providers should note that the treatment of lymphedema with the application of high  
 2 compression bandage systems continues to be non-covered by Medicare. However, a brief  
 3 period (i.e., three or fewer sessions if no new specific issues are identified) of patient and/or  
 4 caregiver education for home management of lymphedema with compression wrap  
 5 applications may be medically necessary and reimbursable. Medical necessity for the  
 6 education must be clearly indicated in the patient's record and must meet the code  
 7 descriptor requirements for CPT® 97535, supporting home management training. S8430 –  
 8 padding for compression bandage, roll and S8431 – compression bandage, roll may be  
 9 appropriate and allowable per health plan benefit.

### 11 ***DESCRIPTION***

12 Complex lymphedema therapy (CLT) is a non-invasive treatment for lymphedema with the  
 13 aim of reducing and controlling the amount of swelling in the affected limb and restoring  
 14 function. CLT is a noninvasive treatment that is considered a standard of care for  
 15 lymphedema. This method has also been referred to as complete decongestive  
 16 physiotherapy (CDP), and complex decongestive therapy (CDT). The treatment aim is to  
 17 reduce and control the amount of swelling in the affected limb and restore function. The  
 18 objective of the technique is to redirect and enhance the flow of lymph through intact  
 19 cutaneous lymphatics. Programs are generally provided on an outpatient basis in the office  
 20 setting or in a lymphedema rehabilitation center or clinic (Lasinski and Boris, 2002;  
 21 MacDonald et al., 2003). The typical CLT program consists of two phases of treatment: a  
 22 treatment phase and a maintenance phase. Phase I, the treatment phase, usually lasts 2 to 4  
 23 weeks. This phase consists of four components (Lawenda et al., 2009):

- 24 • Skin and nail care: The purpose is to inspect skin, provide moisture and prevent  
 25 infection.
- 26 • Manual lymph drainage (MLD): This is a light, massage-like technique that is  
 27 performed for 30–60 minutes and is used to stimulate residual lymphatic vessels to  
 28 carry excess fluid from the affected extremity.
- 29 • Compression bandaging: This involves wrapping multi-layered bandages around  
 30 affected limb.
- 31 • Therapeutic exercise: This includes movement of the limb through a range of  
 32 motion with bandaging in place.

33  
 34 Most patients will be able to progress to a home-based, self-managed program after an  
 35 initial in-office program of 1–2 weeks. Instruction in self-management should begin in the  
 36 first week of therapy. Both patients and family are taught bandaging and exercise  
 37 techniques, as well as the essentials of skin and nail care. After the initial one- to two-week  
 38 program, patients should be re-evaluated to determine whether continued in-office therapy  
 39 is necessary or if treatment can be provided in the home.

1 Phase II, the maintenance phase, consists of life-long self-care to maintain the size of the  
 2 limb. In this phase, the patient maintains and optimizes the results by applying the  
 3 techniques learned in the treatment phase including skin and nail care, wearing an elastic  
 4 sleeve during the day, bandaging the affected limb overnight and exercises (Petrek, 2000).  
 5

### 6 **Duration and Frequency**

7 A program of complex lymphedema therapy provided 2–5 times per week for two weeks  
 8 is generally considered medically necessary for the treatment of primary or secondary  
 9 lymphedema, in the absence of any contraindications. Treatment that goes beyond 4 weeks  
 10 requires additional documentation, including objective findings, to support medical  
 11 necessity.  
 12

### 13 **Contraindications**

14 Absolute contraindications to lymphedema therapy include:

- 15 • Acute infections of the affected limb
- 16 • Venous or arterial obstruction (deep vein thrombosis)
- 17 • Active malignancy confirmed or suspected local disease
- 18 • Unwillingness or inability of the member to participate in the treatment

19  
 20 Relative contraindications to lymphedema therapy include:

- 21 • Suspicion of deep vein thrombosis prior to starting treatment
- 22 • Congestive heart failure
- 23 • When the local massage is performed in area of irradiated soft tissue

24  
 25 Note: Placing an acupuncture needle in a limb at risk of, or exhibiting lymphedema is  
 26 absolutely contraindicated. For more information, see the *Acupuncture Services Medical*  
 27 *Policy/Guideline (CPG 264 – S)* clinical practice guideline.  
 28

### 29 ***GENERAL BACKGROUND***

30 Lymphedema is defined as the excessive and persistent accumulation of protein-rich fluid  
 31 that collects in the interstitial spaces, due to an inefficiency of the lymphatic system (Szuba  
 32 et al., 2002; Leal et al., 2009). Lymphedema occurs primarily as a result of malformation,  
 33 underdevelopment, or acquired disruption of the lymphatic circulation (Szuba et al., 2002).  
 34 Primary lymphedema is due to congenital defects of the lymphatic system, which can affect  
 35 from one to as many as four limbs or other parts of the body and is considered rare (National  
 36 Lymphedema Network, 2011). Secondary lymphedema is acquired and is due to an  
 37 obstruction or interruption in the lymphatic circulation. Secondary lymphedema can  
 38 develop as a result of surgery, radiation, infection or trauma. It is a common treatment-  
 39 related side effect experienced by cancer patients. Patients that undergo surgery for breast  
 40 cancer that includes node dissection or axillary radiation therapy are at high risk of  
 41 developing lymphedema.

1 Historically, lymphedema has been classified into 3 stages based on its severity and on  
 2 observation of the patient’s condition. Currently, the International Society of  
 3 Lymphedema is recognizing a Stage 0 in patients, which refers to a latent or sub-clinical  
 4 condition where swelling is not evident despite impaired lymph circulation. Patients often  
 5 report a feeling of heaviness in the limb; however, many patients are asymptomatic in the  
 6 latency stage. Stage 0 may be present for months or years prior to a patient exhibiting signs  
 7 and symptoms of edema. Stage I lymphedema is referred to as spontaneously reversible  
 8 lymphedema (Lawenda et al., 2009; Bicego et al., 2006) and typically involves pitting  
 9 edema, an increase in limb girth (usually upper extremity), and heaviness. Stage II is also  
 10 known as spontaneously irreversible lymphedema and it is marked by spongy consistency  
 11 of the tissue and non-pitting edema (Bicego et al., 2006). Tissue fibrosis marks the  
 12 beginning of hardening of the limbs and increased girth of extremity and is often found in  
 13 Stage II (Bicego et al., 2006). Stage III is the most advanced stage and is often referred to  
 14 as lymphostatic elephantiasis. During Stage III the swelling is irreversible with tissue being  
 15 fibrotic and unresponsive including patients who present with very large limb(s) size. It is  
 16 associated with a significant increase in the severity of the fibrotic response, tissue volume,  
 17 and other skin changes such as papillomas, cysts, fistulas, and hyperkeratosis (Lawenda et  
 18 al., 2009; Zuther, 2005). With regards to Stage 0, the literature is insufficient to conclude  
 19 that the use of CDT is either clinically effective or ineffective in the treatment of subclinical  
 20 or latent stage of breast cancer-related lymphedema.

21  
 22 The best practice or gold standard for lymphedema treatment is considered CDT,  
 23 also known as complex lymphedema therapy (CLT). CDT is a noninvasive treatment and  
 24 consists of four basic components as follows: skin and nail care, manual lymph drainage  
 25 (MLD), followed by bandaging/compression, education, and exercise. The goal of CDT is  
 26 to reduce and control the amount of swelling in the affected limb and restore function.  
 27 A treatment option that may be used to manage secondary lymphedema is intermittent  
 28 pneumatic compressions (IPC) (vasopneumatic compression) which are often added to  
 29 CDT. However, evidence does not support the addition of IPC to CDT or within any  
 30 treatment plan. Low-level laser therapy (LLLT) is another treatment option that has  
 31 been studied as a treatment when used in conjunction with other standard lymphedema  
 32 treatments. However, low-level laser is currently considered experimental, investigational  
 33 and/or unproven. Exercise demonstrates improvements in function and quality of life  
 34 (QoL), but not in limb reduction. The goal of all conservative treatment is to reduce and  
 35 control the amount of swelling in the affected limb and restore function.

### 36 37 **DOCUMENTATION GUIDELINES**

38 Documentation should support a diagnosis of lymphedema and not tissue edema due to  
 39 other etiologies (chronic venous insufficiency, congestive heart failure, acute infection(s),  
 40 etc.). Recent changes in the patient’s condition as well as prior unsuccessful therapies  
 41 (elevation, bandaging, diuresis, etc.) should be reported to justify the need for skilled  
 42 services.

1 ***EVIDENCE REVIEW***

2 Lymphedema is a common sequela of cancer or its treatment that affects the lymphatic  
 3 transport system that results in failure of lymph node drainage. Secondary lymphedema is  
 4 often a debilitating, chronic, progressive condition that commonly occurs after treatment  
 5 of breast cancer. A number of health professional and patient instigated conservative  
 6 therapies have been developed to help treat this condition. A systematic review  
 7 conducted by Moseley et al. (2007) reviewed the common conservative therapies used  
 8 for management of secondary arm lymphedema as follows: complex physical  
 9 therapy, manual lymphatic drainage, pneumatic pumps, oral pharmaceuticals, low level  
 10 laser therapy, compression bandaging and garments, limb exercises and limb  
 11 elevation. This study found that the more intensive and health care professional driven  
 12 therapies, such as complex physical therapy (skin and nail care, manual lymphatic  
 13 drainage, a multilayer compression bandage and therapeutic exercises), manual lymphatic  
 14 drainage, pneumatic pump and laser level light therapy generally yielded greater  
 15 volume reductions, compared to self-instigated therapies such as compression garment  
 16 wear, exercises and limb elevation. These self-care methods showed reductions, however  
 17 in lesser volumes. All conservative therapies reviewed in this study produced  
 18 improvements in subjective arm symptoms and QoL issues, where these were measured.

19  
 20 Stout et al. (2008) completed a study on Stage 0 lymphedema. They used infrared  
 21 optoelectronic technology to identify those at risk for edema based on volume  
 22 measurements. This technology allows for changes to be noted before they are actually  
 23 visible to the eye. When these changes are noted, treatment initiated immediately may  
 24 prevent the development of further stages of lymphedema. However, there is no standard  
 25 for the treatment of early-stage, subclinical lymphedema. When the diagnosis of breast  
 26 cancer related lymphedema is delayed, therapeutic management requires intensive  
 27 decongestive therapy and life-long maintenance. This study suggested that an early  
 28 intervention protocol with 20- to 30-mm Hg compression garments, significantly reduced  
 29 the affected limb volume to near baseline measures and prevented progression to a more  
 30 advanced stage of lymphedema for at least the first year postoperatively. Further research  
 31 is warranted to confirm the long-term clinical and cost effectiveness of this early  
 32 intervention model compared with a traditional model in treating breast cancer related  
 33 lymphedema.

34  
 35 **Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD), and**  
 36 **Compression Methods**

37 A prospective trial of complete decongestive therapy for upper extremity lymphedema after  
 38 breast cancer was reviewed by Mondry et al. (2004). Patients completed 2-4 weeks  
 39 (median, 2 weeks) of treatment; including skin and nail care, manual lymphatic  
 40 drainage, a multilayer compression bandage and therapeutic exercises. Edema of the  
 41 affected limb was reassessed on a weekly basis. Authors concluded that decreasing girth  
 42 correlated significantly with decreasing visual analogue scale scores for pain, but not

1 with increasing QoL. Data gathered showed median girth reduced 1.5 cm and median  
2 volume reduced 138mL. This study concluded that compliance with the treatment regimen  
3 at home decreased with duration of the program and girth reductions contributed to less  
4 pain. Increased frequency of treatment sessions provides marked improvement in girth,  
5 volume, and weight but resulted in poorer compliance. Longer latency more  
6 successfully reduces girth, volume, and pain and increases QoL. Pain and QoL are  
7 improved by treatment and continue to improve after treatment has ended. A randomized  
8 controlled trial conducted by McNeely et al. (2004) looked at the addition of manual lymph  
9 drainage to compression therapy for managing breast cancer-related lymphedema. The  
10 authors of this study compared the reduction in arm lymphedema volume achieved from  
11 manual lymph drainage massage in combination with multi-layered compression  
12 bandaging to that achieved by compression bandaging alone. Treatment group one  
13 received manual lymph drainage (MLD)/compression bandaging (CB). This group  
14 received 45 minutes of daily MLD and CB, Monday-Friday, for 4 weeks. The second  
15 treatment group received short stretch bandaging, Monday-Friday, for 4 weeks.  
16 Authors concluded that a significant reduction in lymphedema volume was found over the  
17 4-week period for both the manual lymph drainage/compression bandaging and  
18 compression bandaging alone groups. No significant differences existed between  
19 groups (McNeely et al., 2004).

20  
21 Koul et al. (2007) assessed the results of combined decongestive therapy and manual  
22 lymphatic drainage in patients with breast cancer-related lymphedema over a two-year  
23 period. This study was a non-randomized clinical trial that reviewed data from 250 patients  
24 with a final analysis reviewed from 138 patients. The pre- and post-treatment volumetric  
25 measurements were compared and correlated with age, body mass index, and type of  
26 surgery, chemotherapy, and radiotherapy. One group was treated with all 4 parts of  
27 combined decongestive therapy for 1 hour daily for up to several weeks, depending on the  
28 severity and response. Combined decongestive therapy consisted of manual lymphatic  
29 drainage, compression, exercises for the arm and shoulder, and deep breathing to help  
30 promote venous and lymphatic flow. Patients were also fitted with custom-made  
31 garments to be worn daily while awake and removed at bedtime. Self-lymph drainage at  
32 least once daily was also recommended. A second treatment group received MLD alone.  
33 They were also fitted for custom compression garments. Self-lymph drainage was also  
34 recommended. A third treatment group received one hour of home instruction and  
35 counseling, including simple self-drainage techniques, skin care, and exercise. They also  
36 received custom compression garments. Results noted a significant reduction in arm  
37 volumes at 1 year after the beginning of treatment with some or all components of  
38 combined decongestive therapy in patients with lymphedema after breast cancer treatment.

39  
40 Patients with moderate to severe lymphedema had a maximal response after combined  
41 decongestive therapy, and patients enrolled in the home program had mild lymphedema  
42 and less dramatic responses to treatment. Authors concluded that combined

1 decongestive therapy and manual lymphatic drainage with exercises were associated with  
2 a significant reduction in the lymphedema volume in all groups assessed. Long-term  
3 management of breast cancer-related lymphedema after intensive decongestive therapy  
4 was studied by Vignes et al. (2007). The authors' aim was to describe the effect of the  
5 maintenance therapy on lymphedema volume reduction and to analyze the impact of the  
6 different components of treatment in women with upper limb lymphedema after breast  
7 cancer treatment. The treatment consisted of an intensive phase of CDT, including manual  
8 lymph drainage (30 minutes, 5 times a week), low stretch compression bandaging (24 hours  
9 daily), exercises after bandages were applied to enhance lymphatic flow from peripheral  
10 to central compartments and skin care. Maintenance therapy consisted of  
11 education (3 bandages per week). Authors concluded that bandaging and elastic  
12 sleeves are a key component to maintenance therapy after intensive CDT.

13  
14 A systematic review was conducted by Karki et al. (2009) on the effects and harms of  
15 physiotherapy methods of lymphedema therapy in breast cancer patients. Fourteen  
16 randomized controlled studies were included, two of which had moderate risk of bias, and  
17 the remainder had high risk. There was moderate evidence that compression bandages  
18 alone decreased lymphedema, and that pneumatic pumps had no effect on  
19 lymphedema compared to no treatment. With the remainder of the studies that had high  
20 risk of bias, the interventions and comparisons varied across all trials. This review found  
21 moderate evidence to support compression bandages decreased lymphedema. There  
22 was no evidence regarding volume reduction outcomes in any other body part except the  
23 upper limb. Evidence on other physiotherapy methods and combinations is limited due to  
24 poor quality of the studies. Devoogdt et al. (2010) conducted a systematic review of  
25 combined physical therapy, intermittent compression, and arm elevation for treatment of  
26 lymphedema secondary to axillary dissection for breast cancer. The review included  
27 ten randomized controlled trials and non-randomized, experimental trials. The review  
28 found that combined physical therapy can be considered as an effective treatment modality  
29 for treatment of lymphedema; however, the effectiveness of its different components  
30 remains uncertain. Szolnoky et al. (2009) compared manual lymphatic drainage with  
31 manual lymphatic drainage plus intermittent pneumatic compression for treatment  
32 of unilateral arm lymphedema in 27 women previously treated for breast cancer.  
33 One treatment group received complex decongestive physiotherapy (CDP), which  
34 included manual lymph drainage (MLD) using the Vodder technique. Treatment sessions  
35 were for 60 minutes per day for 10 consecutive business days by a specific physiotherapist,  
36 followed by skin care, bandaging, and exercise. MLD was performed on the neck,  
37 breast, and abdomen. The second treatment group received complex decongestive  
38 physiotherapy plus intermittent pneumatic compression (CDP+IPC). This included  
39 the same MLD using the Vodder technique for 30 minutes per day for 10 days, followed  
40 by 30 minutes of IPC with a Lympha Mat device at a pressure of 50 mmHg. Patients also  
41 received skin care, bandaging, and exercise. Each treatment method was effective in  
42 reducing limb size, but the combination treatment of CDP+IPC showed statistically

1 significant greater reductions in limb size when compared to CDP alone, with no negative  
 2 side effects noted. No other statistically significant changes were noted in the patients'  
 3 subjective reports with either treatment method at any time.

4  
 5 A technology assessment requested by Centers for Medicare and Medicaid Services (CMS)  
 6 was conducted by McMaster University Evidence-based Practice Center for the Agency  
 7 for Healthcare Research and Quality (AHRQ) (Oremus et al., 2010) diagnosis and  
 8 treatment of secondary lymphedema. The review included randomized controlled trials or  
 9 observation studies with comparison groups (e.g., cohort, case control). The assessment  
 10 concluded the following:

- 11 • CDT has been observed to have a significant effect on edema reduction and is  
 12 recognized internationally as a successful treatment for lymphedema.
- 13 • There is no single treatment that is considered usual care for lymphedema. At this  
 14 time, CDT, which is a combination of therapies, is suggested as the main method  
 15 of conservative care for lymphedema. CDT includes manual lymphatic drainage  
 16 (MLD), application of compression low stretch bandages, exercise, and skin care.

17  
 18 A randomized controlled-group study conducted by Kim et al. (2010) investigated the  
 19 differences between the effects of complex decongestive physiotherapy with and without  
 20 active resistive exercise for the treatment of patients with breast cancer-related  
 21 lymphedema. Treatment group one received CDT (manual lymphatic  
 22 drainage, compression therapy, and exercise, including resistance training) 5 times a  
 23 week for 2 weeks followed by self-administered treatment for another 6 weeks. The control  
 24 group received the CDT without the resistance training added to the exercise program.  
 25 Authors concluded that active resistive exercise with CDT did not create additional  
 26 swelling and assisted with reduction of arm volume. QoL was also improved for this group.  
 27 The National Lymphedema Network (NLN) published a position statement regarding  
 28 treatment of lymphedema (2011). Included in the document were the following statements  
 29 regarding CDT:

- 30 • CDT is the main treatment for lymphedema. Experts who treat lymphedema  
 31 consider CDT the “gold standard” of treatment. The treatment has been shown to  
 32 be safe and effective. CDT is the current international standard of care for managing  
 33 lymphedema.
- 34 • CDT has been shown to be effective in large numbers of case studies demonstrating  
 35 limb volume reductions of 50–70% or more, improved appearance of the limb,  
 36 reduced symptoms, improved quality of life, and fewer infections after treatment.  
 37 Even people with progressive lymphedema for 30 years or more before starting  
 38 CDT have been shown to respond.
- 39 • Patient adherence during Phase II CDT is critical for preserving volume reduction.

- It is recommended that CDT adaptations or other lymphedema treatments be used on a case-by-case basis under the supervision of a healthcare provider (e.g., physician, nurse, physician assistant, therapist) with demonstrated expertise in lymphedema management.

In 2020, the International Society of Lymphology (ISL) published an updated consensus document regarding the diagnosis and treatment of peripheral lymphedema. The document makes the following notes regarding lymphedema treatment that was consistent with their 2013 consensus statements:

- CDT is included in the statement as a standard treatment for lymphedema that is backed by longstanding experience. The first phase includes skin care, light manual massage, range of motion exercise and compression with multilayered bandage-wrapping. The second phase aims to conserve and optimize results obtained in Phase 1.
- An assessment should be made of limb volume before, during and after treatment. Treatment outcomes should be reported in a standardized manner in order to assess effectiveness of treatment protocols.

Hwang et al. (2013) completed a systematic review and meta-analysis on the effects of MLD on breast cancer-related lymphedema. They investigated whether manual lymphatic drainage (MLD) could prevent or manage limb edema in women after breast-cancer surgery. In total, 10 RCTs with 566 patients were identified. Authors concluded that the current evidence from RCTs does not support the use of MLD in preventing or treating lymphedema. However, clinical and statistical inconsistencies between the various studies confounded our evaluation of the effect of MLD on breast-cancer-related lymphedema. Lasinski (2013) summarized the evidence on the management of lymphedema and provided recommendations. CDT is effective in reducing lymphedema, although the contribution of each individual complete decongestive therapy component has not been determined. In general, levels of evidence for complete decongestive therapy are moderate. Fu et al. (2014) aimed to provide healthcare professionals with evidence-based clinical practice guidelines for lymphedema treatment and management through a systematic review. Findings of the systematic review support complete decongestive therapy, compression bandages, and compression garments with the highest evidence for best clinical practice. Weight management, full-body exercise, education, prevention, and early intervention protocols are likely to be effective for clinical practice.

Shao et al. (2014) sought to determine whether the use of an intermittent pneumatic pump (IPC) could manage lymphedema effectively. Seven randomized controlled trials, with 287 patients, were included. Results showed that the use of the IPC could alleviate lymphedema, but no significant difference between routine management of lymphedema with or without pneumatic pump existed. Authors concluded that current trials fail to show the effectiveness of the addition of an IPC to the routine management of BCRL. Leung et

1 al. (2015) evaluated the available evidence for the treatment of secondary lower limb  
 2 lymphoedema in patients with malignancies. Authors concluded that few studies have  
 3 evaluated the clinical effectiveness and potential side effects of treatments for lower limb  
 4 lymphoedema. Moreover, symptoms and quality-of-life assessments were inconsistently  
 5 reported. All included studies report lower limb volume reduction after treatment, which  
 6 includes complex decongestion therapy, graded compression stockings and lymphovenous  
 7 microsurgical shunts. Adequately powered randomized controlled trials of these  
 8 interventions are recommended. Ezzo et al. (2015) assessed the efficacy and safety of MLD  
 9 in treating BCRL. Six trials were included. Authors concluded that MLD is safe and  
 10 may offer additional benefit to compression bandaging for swelling reduction.  
 11 Compared to individuals with moderate-to-severe BCRL, those with mild-to-  
 12 moderate BCRL may be the ones who benefit from adding MLD to an intensive  
 13 course of treatment with compression bandaging. This finding, however, needs to be  
 14 confirmed by randomized data. In trials where MLD and sleeve were compared with a non-  
 15 MLD treatment and sleeve, volumetric outcomes were inconsistent within the same trial.  
 16 Findings were contradictory for function (range of motion), and inconclusive for quality of  
 17 life. For symptoms such as pain and heaviness, 60% to 80% of participants reported feeling  
 18 better regardless of which treatment they received. One-year follow-up suggests that once  
 19 swelling had been reduced, participants were likely to keep their swelling down if they  
 20 continued to use a custom-made sleeve. Finnane et al. (2015) sought to summarize efficacy  
 21 findings of reviews on lymphedema treatment. Overall, there was wide variation in review  
 22 methods. The quality of studies included in reviews, in study design and reporting  
 23 overall, has been poor. Reviews consistently concluded that complex physical therapy is  
 24 effective at reducing limb volume. Volume reductions were also reported after the use of  
 25 compression garments, pumps, and manual lymphatic drainage. However, greatest  
 26 improvements were reported when these treatments formed a combined treatment  
 27 program. Large, well-designed, evaluated, and reported randomized, controlled trials are  
 28 needed to evaluate and compare treatments.

29  
 30 Elastic therapeutic taping (e.g., Kinesio taping) has been proposed as a treatment  
 31 intervention for lymphedema, given its properties and hypothesized mechanism to lift the  
 32 skin away from the adjacent muscle and allow intercellular fluid to flow more freely. For  
 33 example, lymph will move more easily out of lymph channels and into larger lymph ducts  
 34 for uptake. Bialoszewski et al. (2009) studied the effects of KT in reducing edema of lower  
 35 limbs in patients subjected to limb lengthening. Twenty-four patients developed post-  
 36 surgical lymphedema. They were randomized into 2 groups. One group received taping  
 37 and the other received standard physiotherapy (lymphatic drainage). Both methods reduced  
 38 edema significantly pre- and post-treatment (after 10 days); however, the application of  
 39 KT produced a significantly faster reduction of edema compared to standard lymphatic  
 40 drainage methods. A study by Tsai et al. (2009) hypothesized whether KT could replace  
 41 the bandage in decongestive lymphatic therapy (DLT) for breast-cancer-related  
 42 lymphedema. The pilot study looked at standard DLT combined with pneumatic

1 compression (PC) or modified DLT using KT combined with PC; both types of treatments  
 2 resulted in reduced girth measurements of the upper extremity and other outcomes in 41  
 3 patients with breast-cancer-related lymphedema. Results demonstrated no significant  
 4 differences between the two types of treatments. Thus, the use of KT could replace the  
 5 bandage typically used in DLT. Morris et al. (2013) reported on a systematic review with  
 6 the purpose of this study was to investigate the effect of Kinesio Tex tape (KTT) from  
 7 randomized controlled trials (RCTs) in the management of clinical conditions. The review  
 8 included 8 RCTs: 6 included patients with musculoskeletal conditions; 1 with breast-  
 9 cancer-related lymphedema; and 1 included stroke patients with muscle spasticity. Six  
 10 studies included a sham or usual care tape/bandage group. The review found limited to  
 11 moderate evidence that KTT is no more clinically effective than sham or usual care  
 12 tape/bandage. The authors concluded that there currently exists insufficient evidence to  
 13 support the use of KTT over other modalities in clinical practice. Kalron and Bar-Sela  
 14 (2013) reported on a systematic review that assessed the effects of therapeutic Kinesio  
 15 Taping (KT) on pain and disability in participants suffering from musculoskeletal,  
 16 neurological, and lymphatic pathologies. Twelve met inclusion criteria. The final 12  
 17 articles were subdivided according to the basic pathological disorders: musculoskeletal  
 18 ( $N=9$ ) (4 randomized, controlled trials (RCT), 3 single-blinded RCT, 1 cross-over trial and  
 19 one case-control study); neurological ( $N=1$ ) (RCT); and lymphatic ( $N=2$ ) (RCT).  
 20 Regarding lymphatic disorders, inconclusive evidence was reported. The authors  
 21 concluded that although KT has been shown to be effective in aiding short-term pain, there  
 22 is no firm evidence-based conclusion of the effectiveness of this application on the majority  
 23 of movement disorders within a wide range of pathologic disabilities. Gatt et al. (2017)  
 24 aimed to determine the effectiveness and safety of kinesiotope (KT) in the management  
 25 of cancer-related lymphoedema (CRL) compared to compression bandaging or hosiery.  
 26 Five studies were included in the meta-analysis of the primary outcome limb volume ( $n =$   
 27 203, KT  $n = 91$ , compression  $n = 112$ ). No significant difference existed between the  
 28 interventions. An increased risk of skin complications with KT was reported in five studies  
 29 affecting between 10% and 21% of patients. Where lymphoedema-related symptoms  
 30 were reported KT was found to be superior to compression. Paradoxically,  
 31 patients receiving bandaging reported a higher QoL. Thus, authors concluded that  
 32 KT was not found to be more comfortable than bandaging and should only be used with  
 33 caution where bandaging cannot be used.

34  
 35 Torres-Lacombe et al. (2020) compared the effects of four types of bandages and kinesio-  
 36 tape and determine which one is the most effective in women with unilateral breast cancer-  
 37 related lymphoedema. A total of 150 women presenting breast-cancer-related  
 38 lymphoedema were randomized into five groups ( $n = 30$ ). All women received an intensive  
 39 phase of complex decongestive physiotherapy including manual lymphatic drainage,  
 40 pneumatic compression therapy, therapeutic education, active therapeutic exercise, and  
 41 bandaging. The only difference between the groups was the bandage or tape applied  
 42 (multilayer; simplified multilayer; cohesive; adhesive; kinesio-tape). The main outcome

1 was percentage excess volume change. Other outcomes measured were heaviness and  
 2 tightness symptoms, and bandage or tape perceived comfort. Data was collected at baseline  
 3 and finishing interventions. This study showed significant differences between the bandage  
 4 groups in absolute value of excess volume. The five groups exhibited a significant decrease  
 5 in symptoms after interventions, with no differences between groups. In addition, kinesio-  
 6 tape was perceived as the most comfortable by women and multilayer as the most  
 7 uncomfortable ( $P < 0.001$ ). The most effective were the simplified multilayer and the  
 8 cohesive bandages. The bandages/tape with the least difference were kinesio- and adhesive  
 9 bandages.

10  
 11 Zasadzka et al. (2018) compared the effectiveness of multi-layer compression  
 12 bandaging (MCB) and CDT for treating lymphedema in elderly patients. One  
 13 hundred three patients (85 women and 18 men) aged  $\geq 60$  years, with unilateral lower  
 14 limb lymphedema. The subjects were divided into two groups: 50 treated with CDT  
 15 and 53 with MCB. Pre- and post-treatment BMI, and average and maximum  
 16 circumference of the edematous extremities were analyzed. Results noted a reduction  
 17 in swelling in both groups was achieved after 15 interventions. Both therapies  
 18 demonstrated similar efficacy in reducing limb volume and circumference, but MCB  
 19 showed greater efficacy in reducing the maximum circumference. Authors concluded  
 20 that compression bandaging is a vital component of CDT. Maximum lymphedema  
 21 reduction during therapy and maintaining its effect cannot be achieved without it.

22 Sezgin Ozcan et al. (2018) evaluated the effects of CDT on upper extremity  
 23 functions, the severity of pain, and quality of life. A total of 37 women with breast  
 24 cancer-related lymphedema (BCRL) [age,  $53.6 \pm 11.2$  (28-72)] were included in this  
 25 study. All patients underwent CDT-phase 1 program, including meticulous skin care,  
 26 manual lymphatic drainage, remedial exercises, and compression bandages. The  
 27 mean of the post-treatment volume of the affected limb was lower compared to  
 28 pretreatment volume. A statistically significant reduction in pain and heaviness VAS  
 29 scores and improvement of shoulder mobility among upper extremities with  
 30 lymphedema ( $p < 0.001$ ) was noted after CDT. The mean of post-treatment DASH  
 31 score was lower, and all subgroups of the SF-36 parameters were increased after the  
 32 CDT application. Also, being under 65 years old, having a body mass index above  
 33 30 and short duration of lymphedema were found to be related to greater  
 34 improvement in upper extremity functions. Authors concluded that CDT provides  
 35 enhancement of upper extremity functions and quality of life in patients with BCRL.

36  
 37 Michopoulos et al. (2020) evaluated the effectiveness and safety of CDT of phase I in the  
 38 Greek population with lymphedema. CDT was implemented in all patients for 20 sessions  
 39 in a 4-week treatment period. The edema's (excess volume (EV) and percent of excess  
 40 volume (PEV)) measurements were carried out four times in the treatment period, whereas  
 41 the percent reduction of excess volume (PREV) was calculated at the end of phase I. Every  
 42 infection, trauma of skin, and pain of limb during the treatment was also recorded. One

1 hundred five patients with lymphedema were enrolled, of whom 31.4% had upper limb  
 2 lymphedema and 68.6% had lower limb lymphedema. A significant reduction between the  
 3 pre-treatment and post-treatment values of EV and PEV was found for both upper and  
 4 lower limb lymphedema. For patients with upper limb lymphedema, the average PREV  
 5 was 66.5%, whereas for patients with lower limb lymphedema, a 71.5% median value was  
 6 measured. No side effects from the treatment were recorded during CDT. Authors  
 7 concluded that the proper treatment of the CDT phase I ensures safety and a great reduction  
 8 in edema in patients with lymphedema that predisposes the success of phase II of CDT.

9  
 10 Watanabe et al. (2020) authored an article on the development and themes of diagnostic  
 11 and treatment procedures for secondary leg lymphedema in patients with gynecologic  
 12 cancers. They note that for the treatment of lymphedema, complex decongestive  
 13 physiotherapy (CDP) including manual lymphatic drainage (MLD), compression therapy,  
 14 exercise, and skin care, are generally performed. In recent years, CDP has often required  
 15 effective multi-layer lymph edema bandaging (MLLB) or advanced pneumatic  
 16 compression devices (APCDs). If CDP is not effective, microsurgical procedures can be  
 17 performed. They conclude that the most important concern is the prevention of secondary  
 18 lymphedema, which is achieved through approaches such as skin care, weight control,  
 19 gentle limb exercises, avoiding sun and heat, and elevation of the affected leg.

20  
 21 In accordance with the most recent Consensus Document of the International Society of  
 22 Lymphology (2020), CDT should include two phases: 1. Phase I: characterized by skincare,  
 23 manual lymphatic drainage (MLD), with or without deeper techniques including muscle  
 24 pumping exercises or hydraulic pressotherapy, followed by multilayer compression  
 25 bandage, aiming at improving lymphedema volume; 2. Phase II: characterized by skincare  
 26 and compression garments wearing, including low stretch elastic stocking or sleeve, aiming  
 27 at avoiding complications and conserving the results obtained in Phase I.

28  
 29 Thompson et al. (2021) evaluated the effectiveness of MLD for those at-risk of or living  
 30 with lymphedema. Seventeen studies with a total of 867 female and two male participants  
 31 were included. Only studies examining breast cancer-related lymphedema were identified.  
 32 Some studies reported positive effects of MLD on volume reduction, quality of life and  
 33 symptom-related outcomes compared with other treatments, while other studies reported  
 34 no additional benefit of MLD as a component of complex decongestive therapy. In patients  
 35 at-risk, MLD was reported to reduce the incidence of lymphedema in some studies, while  
 36 others reported no such benefits. Authors concluded that reviewed articles reported  
 37 conflicting findings and were often limited by methodological issues. They suggest the  
 38 need for further experimental studies on the effectiveness of MLD in lymphedema. There  
 39 is some evidence that MLD in early stages following breast cancer surgery may help  
 40 prevent progression to clinical lymphedema. MLD may also provide additional benefits in  
 41 volume reduction for mild lymphedema. However, in moderate to severe lymphedema,

1 MLD may not provide additional benefit when combined with complex decongestive  
2 therapy.

3  
4 Kalemikerakis et al. (2021) authored an article on the diagnosis and management of cancer-  
5 related lymphedema. They note that early diagnosis and treatment of lymphedema is  
6 related with better therapeutic outcomes. Women with breast cancer confront more  
7 problems with lymphedema than with mastectomy. Its effect on patients' quality of life is  
8 relevant to changes in body image, self-esteem, feelings of weakness, fear and anxiety  
9 about disease progression, financial costs, and reduced limb function. Relative to  
10 conservative management, authors summarize that CDT remains the treatment of choice  
11 and in combination with exercise, weight control programs and self-care training seems to  
12 significantly improve patients' quality of life. Forner-Cordero et al. (2021) assessed  
13 whether treatment with intermittent pneumatic compression plus multilayer bandages is  
14 not inferior to classical trimodal therapy with manual lymphatic drainage in the  
15 decongestive lymphedema treatment. 194 lymphedema patients, stage II-III with excess  
16 volume > 10% were stratified within upper and lower limb and then randomized to one of  
17 the three treatment groups. Baseline characteristics were comparable between the groups.  
18 For interventions all patients were prescribed 20 sessions of the following regimens: Group  
19 A (control group): manual lymphatic drainage + Intermittent Pneumatic Compression +  
20 Bandages; Group B: pneumatic lymphatic drainage + Intermittent Pneumatic Compression  
21 + Bandages; and Group C: only Intermittent Pneumatic Compression + Bandages. The  
22 outcome was the percentage reduction in excess volume (PREV). Results demonstrated  
23 that all patients improved after treatment. Global mean of PREV was 63.9%, without  
24 significant differences between the groups. Most frequent adverse events were discomfort  
25 and lymphangitis, without differences between groups. A greater baseline edema, an upper-  
26 limb lymphedema and a history of dermatolymphangitis were independent predictive  
27 factors of worse response in the multivariate analysis. Authors concluded that decongestive  
28 lymphatic therapy performed only with intermittent pneumatic compression plus bandages  
29 is not inferior to the traditional trimodal therapy with manual lymphatic drainage. This  
30 approach did not increase adverse events.

31  
32 McNeely et al. (2022) examined the efficacy of nighttime compression as a self-  
33 management strategy for women with chronic breast cancer-related lymphedema. Authors  
34 conducted a parallel 3-arm, multicenter, randomized trial. Women were recruited from 3  
35 centers in Canada and randomized to group 1 (daytime compression garment alone  
36 [standard care]), group 2 (daytime compression garment plus nighttime compression  
37 bandaging), or group 3 (daytime compression garment plus the use of a nighttime  
38 compression system garment). The primary outcome was the change in excess arm volume  
39 from the baseline to 12 weeks. Participants from all groups used a nighttime compression  
40 system garment from weeks 13 to 24. One hundred twenty women were enrolled, 118  
41 completed the randomized trial, and 114 completed the 24-week follow-up. The rates of  
42 adherence to nighttime compression were 95% ± 15% and 96% ± 11% in the compression

1 bandaging and nighttime compression system groups, respectively. After the intervention,  
 2 the addition of nighttime compression was found to be superior to standard care for both  
 3 absolute milliliter reductions ( $P = .006$ ) and percentage reductions ( $P = .002$ ) in excess arm  
 4 lymphedema volume. Significant within-group changes were seen for quality of life across  
 5 all groups; however, no between-group differences were found ( $P > .05$ ). Authors  
 6 concluded that this study demonstrated a significant improvement in arm lymphedema  
 7 volume from the addition of nighttime compression whether through the application of  
 8 compression bandaging or through the use of a nighttime compression system garment.

9  
 10 De Vrieze et al. (2022) investigated the effect of fluoroscopy-guided manual lymphatic  
 11 drainage (MLD) versus traditional MLD or placebo MLD for the treatment of breast  
 12 cancer-related lymphoedema (BCRL) when added to decongestive lymphatic therapy  
 13 (DLT). All participants received standard DLT (education, skin care, compression therapy  
 14 and exercises). Participants were randomized to also receive fluoroscopy guided MLD  
 15 ( $n = 65$ ), traditional MLD ( $n = 64$ ) or placebo MLD ( $n = 65$ ). Participants received  
 16 14 sessions of physiotherapy during the 3-week intensive phase and 17 sessions during the  
 17 6-month maintenance phase. Participants performed self-management on the other days.  
 18 All outcomes were measured: at baseline; after the intensive phase; after 1, 3 and 6 months  
 19 of maintenance phase; and after 6 months of follow-up. The primary outcomes were  
 20 reduction in excess volume of the arm/hand and accumulation of excess volume at the  
 21 shoulder/trunk, with the end of the intensive phase as the primary endpoint. Excess  
 22 lymphoedema volume decreased after 3 weeks of intensive treatment in each group. The  
 23 effect of fluoroscopy guided MLD was very similar to traditional MLD and placebo MLD.  
 24 Authors concluded that in patients with chronic BCRL, MLD did not provide clinically  
 25 important additional benefit when added to other components of DLT.

26  
 27 Borman et al. (2022) evaluated the effects of CDT in patients with breast cancer-related  
 28 lymphedema (BCRL), in regard to volume reduction, functional status and QoL. Fifty  
 29 patients with unilateral BCRL were included. All patients received combined phase 1 CDT  
 30 including skincare, manual lymphatic drainage, multilayer bandaging, and supervised  
 31 exercises, 5 times a week for 3 weeks, as a total of 15 sessions. Patients were assessed by  
 32 limb volumes and excess volumes. The functional disability was evaluated by quick  
 33 disability of arm, shoulder, and hand questionnaire (Q-DASH). QoL was assessed by the  
 34 European Organization for Research and Treatment of Cancer Core Cancer Quality of Life  
 35 Questionnaire (EORTC QLQ-C30) and its breast-cancer-module (EORTC QLQ-BR23).  
 36 Fifty females with mean age of  $53.22 \pm 11.2$  years were included. The median duration of  
 37 lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients  
 38 in stage3. The mean baseline limb and excess volumes were significantly decreased at the  
 39 end of therapies. The Q-DASH and EORTC QLQ-C30 and BR23 scores also decreased  
 40 significantly. The improvements in volumes were related negatively with the duration of  
 41 lymphedema, and the stage of lymphedema. Authors concluded that CDT in a combined

1 manner performed daily for 3 weeks greatly reduces the volumes as well as improves the  
2 disability and QoL, especially when performed earlier.

3  
4 de Sire et al. (2022) completed a review to characterize the comprehensive management of  
5 lymphedema, providing a broad overview of the potential therapy available in the current  
6 literature. They conclude that a multidisciplinary treatment should be truly integrated for  
7 lymphedema patients, and rehabilitation should be considered the cornerstone of the  
8 multidisciplinary treatment not only for patients not suitable for surgical interventions but  
9 also before and after surgical procedures. Rehabilitation should include (CDT), which  
10 includes manual lymph drainage (MLD), skin care, specialized exercises, compression  
11 garments and self-education. Rangan et al. (2022) investigated the immediate, short-term,  
12 and long-term effects of complex physical therapy and multimodal approaches on  
13 lymphedema secondary to breast cancer. Fourteen studies were identified for systematic  
14 review and 11 studies for the meta-analysis. The common outcomes involved total volume,  
15 pain, and physical function of the upper limb. Complex physical therapy has shown a  
16 favorable tendency to control outcomes in the short- and long-term. The meta-analysis  
17 indicated a small effect for volume reduction and a moderate effect for short-term pain  
18 reduction. Authors concluded that high-quality evidence suggests a more significant effect  
19 of complex physical therapy on multimodal approaches to the control of the upper limb  
20 total volume, substantiating the absence of changes in the current clinical practice in the  
21 management of lymphedema secondary to breast cancer. Future research should aim to  
22 identify concrete effects of therapeutic modalities in the immediate-, short-, and long-term.

23  
24 Lin et al. (2022) analyzed the effectiveness of manual lymphatic drainage (MLD) in breast  
25 cancer-related lymphedema (BCRL) patients in a systematic review and meta-analysis. In  
26 total, 11 RCTs involving 1,564 patients were included, in which 10 trials were deemed  
27 viable for inclusion in the meta-analysis. Due to the effects of MLD for BCRL, statistically  
28 significant improvements were found on the incidence of lymphedema and pain intensity.  
29 Besides, the meta-analysis carried out implied that the effects that MLD had on volumetric  
30 changes of lymphedema and quality of life, were not statistically significant. The current  
31 evidence based on the RCTs shows that pain of BCRL patients undergoing MLD is  
32 significantly improved, while our findings do not support the use of MLD in improving  
33 volumetric of lymphedema and quality of life. Torgbenu et al. (2023) aimed to describe  
34 and compare international guidelines on lymphedema diagnosis, assessment, and  
35 management. This systematic review of 1,564 articles and 159 web pages yielded 14  
36 guidelines. All guidelines were from high-income countries. Ten focused exclusively on  
37 lymphedema, and four on cancer. Most (n = 13) guidelines recommended an integrated  
38 medical, psychological assessment, and physical examination, with a limb volume  
39 measurement of >10% in the affected limb compared, confirming a lymphedema diagnosis.  
40 Recommended management involved Complex Decongestive Therapy (CDT) followed by  
41 self-management using skincare, self-lymphatic drainage massage, exercise, and  
42 compression.

1 Qiao et al. (2023) analyzed the efficacy of MLD for BCRL. A total of 457 patients were  
 2 included in the analysis. There was no significant difference in the amount of upper  
 3 extremity edema between the MLD treatment and control or no MLD groups. However,  
 4 when the treatment course was  $\geq 20$  sessions, there was a significant reduction in the upper  
 5 extremity volume. There was also a significant reduction in the upper extremity volume  
 6 when treatment duration was  $> 2$  weeks. Authors concluded that manual lymphatic drainage  
 7 treatment statistically did not reduce the upper extremity limb volume of BCRL, but upper  
 8 extremity volume was reduced at statistically significant levels when treatment number  
 9 were  $\geq 20$  sessions or the duration of treatment was  $> 2$  weeks.

10  
 11 Donahue et al. (2023) summarized current BCRL prevention and treatment strategies. They  
 12 report that complete decongestive therapy (CDT) remains the standard of care for patients  
 13 with BCRL. Intermittent pneumatic compression, nonpneumatic active compression  
 14 devices, and low-level laser therapy appear promising in lymphedema management.  
 15 Currently, no pharmacological approaches have proven successful. Senger et al. (2023)  
 16 summarized current concepts in primary lymphedema. Primary lymphedema is a  
 17 heterogeneous group of conditions encompassing all lymphatic anomalies that result in  
 18 lymphatic swelling. Primary lymphedema can be difficult to diagnose, and diagnosis is  
 19 often delayed. As opposed to secondary lymphedema, primary lymphedema has an  
 20 unpredictable disease course, often progressing more slowly. Primary lymphedema can be  
 21 associated with various genetic syndromes or can be idiopathic. Diagnosis is often clinical,  
 22 although imaging can be a helpful adjunct. The literature on treating primary lymphedema  
 23 is limited, and treatment algorithms are largely based on practice patterns for secondary  
 24 lymphedema. The mainstay of treatment focuses on complete decongestive therapy,  
 25 including manual lymphatic drainage and compression therapy. For those who fail  
 26 conservative treatment, surgical treatment can be an option. Microsurgical techniques have  
 27 shown promise in primary lymphedema, with both lymphovenous bypass and vascularized  
 28 lymph node transfers demonstrating improved clinical outcomes in a few studies.

29  
 30 Marotta et al. (2023) aimed to assess the role of KT among the CDT to treat BCRL.  
 31 Rehabilitation has a key role in the comprehensive management of this condition with  
 32 several studies reporting positive results after performing complex decongestive therapies  
 33 (CDT) in women. Kinesio taping (KT) is a rather recent therapeutic approach to treat  
 34 BCRL, however, evidence in literature regarding its effectiveness is far from being fully  
 35 characterized. Out of the documents identified, 123 were eligible for data screening, and  
 36 only 7 RCTs satisfied the eligibility criteria and were included. Authors found that KT  
 37 might have a positive effect on limb volume reduction in patients with BCRL, studies are  
 38 of low quality. Authors concluded that this systematic review showed that KT did not  
 39 significantly reduce the upper limb volume in BCRL women, though it seemed to increase  
 40 the flow rate during the passive exercise. Further high-quality-studies are needed to  
 41 improve the knowledge to include KT into a multidisciplinary rehabilitative approach for  
 42 the management of BC survivors affected by lymphedema.

1 Cheng et al. (2023) identified and appraised the current evidence for rehabilitation  
 2 interventions in HNCaL. Of 1,642 citations identified, 23 studies (1.4%; n = 2,147 patients)  
 3 were eligible for inclusion. Six studies (26.1%) were randomized clinical trials (RCTs) and  
 4 17 (73.9%) were observational studies. Five of the 6 RCTs were published during 2020 to  
 5 2022. Most studies had fewer than 50 participants (5 of 6 RCTs; 13 of 17 observational  
 6 studies). Studies were categorized by intervention type, including standard lymphedema  
 7 therapy (11 studies [47.8%]) and adjunct therapy (12 studies [52.2%]). Lymphedema  
 8 therapy interventions included standard complete decongestive therapy (CDT) (2 RCTs, 5  
 9 observational studies), modified CDT (3 observational studies), therapy setting (1 RCT, 2  
 10 observational studies), adherence (2 observational studies), early manual lymphatic  
 11 drainage (1 RCT), and inclusion of focused exercise (1 RCT). Adjunct therapy  
 12 interventions included advanced pneumatic compression devices (APCDs) (1 RCT, 5  
 13 observational studies), Kinesio Taping® (1 RCT), photobiomodulation (1 observational  
 14 study), acupuncture/moxibustion (1 observational study), and sodium selenite (1 RCT, 2  
 15 observational studies). Serious adverse events were either not found (9 [39.1%]) or not  
 16 reported (14 [60.9%]). Low-quality evidence suggested the benefit of standard  
 17 lymphedema therapy, particularly in the outpatient setting and with at least partial  
 18 adherence. High-quality evidence was found for adjunct therapy with Kinesio Taping®.  
 19 Low-quality evidence also suggested that APCDs may be beneficial.

20  
 21 McNeely et al. (2024) conducted a rapid review of the literature examining compression  
 22 therapies and therapeutic modalities in the treatment of lymphedema secondary to cancer.  
 23 The electronic search yielded 438 potentially relevant citations with 40 randomized  
 24 controlled trials included in the review, and 30 in the mapping process. Ninety-three  
 25 percent (n = 37) of the trials included participants with a diagnosis of breast cancer. Across  
 26 all categories and domains, all but two trials were rated as having 'some concerns' or a 'high  
 27 risk of bias'. Intervention effects ranged from clinically insignificant to large effects on  
 28 lymphedema volume. Evidence mapping suggests potential for benefit from (1)  
 29 compression garments for the prevention of lymphedema, (2) interventions added to CDT  
 30 in the intensive reduction phase, and (3) nighttime compression and compression pump  
 31 treatments in the maintenance phase. A multi-center collaborative research approach is  
 32 needed to support the conduct of high-quality large-scale trials to inform the optimal type,  
 33 timing, and combination of compression therapies and therapeutic modalities in the  
 34 treatment of lymphedema secondary to cancer.

35  
 36 Gilchrist et al. (2024) presented a systematic review (SR) of SRs on complete decongestive  
 37 therapy (CDT)'s efficacy in breast cancer-related lymphedema (BCRL), and the  
 38 components of manual lymph drainage (MLD) and exercise. A literature search yielded 13  
 39 SRs published between January 2018 and March 2023 meeting inclusion criteria, with  
 40 varied quality ratings based on the AMSTAR II. A sub-analysis of CDT investigated the  
 41 within group effect size estimations on volume in different stages of lymphedema. While  
 42 a moderate quality SR indicated support for CDT in volume reduction, other SRs on the

1 topic were of critically low quality. Larger effect sizes for CDT were found for later stage  
2 BCRL. The impact of MLD as a component of CDT demonstrated no additional volume  
3 benefit in a mix of moderate to low quality SRs. Similarly, exercise's role in volume  
4 reduction in CDT was limited, although it demonstrated some benefit in pain and quality  
5 of life. A rapid review of trials published January 2021-March 2023 reinforced these  
6 findings. Variability in CDT delivery and outcomes remained. These findings underscore  
7 the need to standardize staging criteria and outcome measures in research and practice.  
8 Future research should focus on refining interventions, determining clinically important  
9 differences in outcomes, and standardizing measures to improve evidence-based BCRL  
10 management. Current evidence supports CDT's efficacy in BCRL. MLD and exercise as  
11 components of CDT have limited support for volume reduction.

12  
13 Yang et al. (2024) evaluated the impact of kinesiology taping on individuals suffering from  
14 breast cancer-related lymphedema. Information was extracted from 14 randomized  
15 controlled trials (RCTs). The analyses demonstrated statistically significant improvement,  
16 indicating a preference for kinesiology taping in the outcomes of upper limb functional  
17 assessment, quality of life, and perceived comfort. These findings suggest that kinesiology  
18 taping could be considered a viable option for individuals dealing with BCRL.  
19 Nevertheless, acknowledging certain limitations within this study, further confirmation of  
20 its benefits necessitates additional larger-scale and better-designed RCTs.

21  
22 Tümkaya et al. (2025) mapped out evidence on interventions for reducing lower limb  
23 lymphedema incidence and symptoms after gynecological cancer surgery. The review  
24 included 15 interventions primarily designed to prevent and manage cancer-related lower  
25 extremity lymphedema. Most studies have examined the effect of interventions on the  
26 development of lymphedema-related symptoms and quality of life. Most studies tested  
27 complex decongestive therapy (CDT) (n = 6, 39.9%), including various techniques, such  
28 as manual lymphatic drainage, compression, exercise, and skincare. Of the interventions,  
29 86.6% improved at least one outcome measurement, such as quality of life, lymphedema  
30 incidence, symptoms, and lower limb volume. Authors concluded that limited evidence  
31 shows that the use of interventions appears to have the potential to reduce the risk and  
32 symptoms of lymphedema and improve the quality of life in women undergoing  
33 gynecological cancer treatment.

34  
35 García-Chico et al. (2025) compared the effectiveness of different bandaging techniques  
36 in patients with BCRL. A total of 21 RCTs were included in the systematic review (n =  
37 1,122) and five could be meta-analyzed (n = 239). The meta-analysis did not reveal  
38 significant differences in the reduction of the affected arm volume among different  
39 bandaging techniques, including multilayer, kinesiio-taping, cohesive, and alginate  
40 bandage. Authors concluded that the current scientific evidence does not suggest a clear  
41 advantage of one bandaging technique over another, including kinesiio-taping and  
42 multilayer bandages. Further studies with larger sample sizes are warranted to better

1 understand their potential benefits across the different stages and phases of BCRL  
2 management.

3  
4 Shahshenas et al. (2025) evaluated the effects of lymphatic drainage techniques on  
5 symptom severity, functional outcomes, nerve conduction parameters, and pain relief in  
6 patients with carpal tunnel syndrome (CTS). Studies assessing the effects of lymphatic  
7 drainage techniques (MLD, Kinesio taping, or compression therapy) on CTS-related  
8 outcomes were included. Primary outcomes included the Boston Symptom Severity Scale  
9 (BSSS), Boston Functional Status Scale (BFSS), Visual Analog Scale (VAS), median  
10 nerve cross-sectional area (CSA), hand grip strength, and nerve conduction studies. Twelve  
11 studies met the inclusion criteria, with a total of 479 participants. The between-group meta-  
12 analysis revealed significant pain reduction and improvements in CSA. Median nerve  
13 motor and sensory velocities also improved significantly. However, BSSS and BFSS did  
14 not show significant differences between groups. The within-group analysis demonstrated  
15 significant improvements in symptom severity and functional status. The subgroup  
16 analysis showed that treatment benefits were sustained over time, with no significant  
17 differences between short-term and long-term follow-ups. Authors concluded that  
18 lymphatic drainage techniques offer a promising non-invasive approach for CTS,  
19 decreasing pain, reducing edema, and enhancing nerve conduction. While intra-group  
20 improvements were notable, limited between-group differences were observed.

21  
22 de-la-Cruz-Fernández et al. (2025) analyzed the latest literature concerning the efficacy of  
23 physical therapy interventions in treating secondary lymphedema in patients with head and  
24 neck cancer. A total of four randomized controlled trials were included. They comprise  
25 167 patients, and only one of the studies achieved a low risk of bias. Interventions were  
26 kinesio taping, compression therapy, manual lymphatic drainage and/or exercise applied  
27 in combination with skin care and self-management. Some adverse effects related to  
28 intervention were mild and transitory. Authors conclude that the findings shown by this  
29 review were that an exercise program plus manual lymphatic drainage supplemented with  
30 kinesio taping or compression therapy could be beneficial for external lymphedema.  
31 Neither therapy achieved an improvement in internal lymphedema.

32  
33 Cheville et al. (2025) provided an overview of lymphatic function and lymphedema  
34 pathogenesis with focused discussion of the unique characteristics of cancer related  
35 lymphedema (CRL) including natural history, clinical presentation, and risk factors for  
36 onset and progression in a review. Authors note that multimodal management with  
37 complete decongestive therapy remains first line treatment for CRL, though patient-  
38 specific customization might be required to optimize patients' clinical response and quality  
39 of life.

40  
41 Martín Jiménez et al. (2025) investigated the efficacy of complex decongestive therapy in  
42 patients with chronic venous insufficiency. Secondly, the suitability of manual lymphatic

1 drainage, bandaging, and sequential pneumatic compression therapy - as key compression  
 2 modalities of complex decongestive therapy - was examined. Ten articles exploring the  
 3 efficacy of complex decongestive therapy in patients with chronic venous insufficiency  
 4 were retrieved. The efficacy of the treatment and also the effectiveness of each of the  
 5 maneuvers that make up the complex decongestive therapy studied separately as  
 6 investigated. Lymphatic drainage treatment decreased the venous reflux, edema, clinical  
 7 severity, symptoms, and quality of life. Kinesio taping improved peripheral venous flow,  
 8 ankle function, edema, pain, quality of life, venous symptoms, venous severity disease, and  
 9 mental health. Sequential pneumatic compression increased venous blood flow and quality  
 10 of life, while complex decongestive therapy reduced limb volume and pain intensity and  
 11 improved activities of daily living. Authors concluded that the combined use of these  
 12 techniques is proposed in the symptomatic treatment of VI, just as they are used in the  
 13 treatment of lymphedema. However, further studies are needed to effectively assess CDT  
 14 and define its treatment parameters.

15  
 16 Cheng et al. (2025) compared the effects of compression sleeves and conventional care on  
 17 breast cancer-related lymphedema, providing evidence-based support for clinical  
 18 application (n=1532). Compression sleeves significantly reduced lymphedema incidence  
 19 post-surgery and edema volume/circumference, and improved shoulder flexion. No  
 20 significant effects were seen on shoulder abduction, subjective symptoms, or quality of  
 21 life. Evidence quality was moderate for incidence and volume/circumference reduction,  
 22 and low for other outcomes. This meta-analysis shows that compression sleeves reduce  
 23 lymphedema incidence and volume/circumference and improve shoulder flexion. They  
 24 should be considered in lymphedema management, though further research is needed for  
 25 other outcomes.

26  
 27 Rajaram et al. (2025) conducted a PRISMA 2020 checklist adherent systematic review on  
 28 head and neck lymphedema management. Thirty-seven studies encompassing a sample  
 29 size of 1,452 were discovered from 602 initial results. Overall, the evidence base was weak  
 30 with many case reports and studies. Complete Decongestive Therapy provided the largest  
 31 and most consistent data. Surgical methodologies appear to provide significant benefit  
 32 when cases are selected carefully for appropriateness. Other dermatological and  
 33 pharmaceutical methods are promising but suffer from a lack of evidence.

### 34 35 **Other Treatments**

#### 36 **Low Level Laser Therapy (LLLT)**

37 Carati et al. (2003) performed a double blind, placebo controlled randomized, single  
 38 crossover trial use of low-level laser therapy (LLLT) for a treatment option for patients  
 39 with post mastectomy lymphedema (PML). Participants received either one cycle or two  
 40 cycles of LLLT to the axillary region of their affected arm. The authors monitored for  
 41 reduction in affected limb volume, upper body extracellular tissue fluid distribution, dermal  
 42 tonometry and range of motion. The result yielded two cycles of LLLT improved

1 lymphedema; however, limb volume reduction was not immediate and was reported 2-3  
2 months post-treatment (Carati et al., 2003). A study conducted by Dirican et al. (2011)  
3 reviewed the authors' short-term experience with low-level laser therapy in the treatment  
4 of breast-cancer related lymphedema. Treatment consisted of laser therapy using 300mJ  
5 for one minute to 17 different points on the surgical scar tissue of the axilla. Patients  
6 were also treated with compression garments or bandaging. Two of the patients  
7 in the study also had sessions using an intermittent compression device. Authors  
8 concluded that patients with breast cancer gain additional benefits in the form of volume  
9 reduction from low level laser therapy when used in conjunction with other standard  
10 treatments (Dirican et al., 2011). Further studies are needed to confirm these findings. Smoot  
11 et al. (2015) examined the literature on effectiveness of LLLT in reducing limb volume and  
12 pain in adults with breast cancer related lymphedema (BCRL). They concluded that moderate  
13 strength evidence supports LLLT in the management of BCRL. The overall review of  
14 literature investigated conservative therapies for secondary arm lymphedema that can be  
15 divided into intensive treatments administered by trained healthcare professionals and limb  
16 maintenance that are carried out by the patient. Treatments that are predominantly  
17 administered by healthcare professionals, such as CDT, MLD, and pneumatic pump  
18 therapy generally yielded the larger reduction in limb volume. LLLT may be a potential  
19 treatment option, but more well-designed studies are needed. Maintenance therapies  
20 generally carried out by the patient in a self-care program (e.g., wearing compression  
21 garments, performing limb exercises, limb elevation, and self-massage) yielded smaller  
22 limb reduction.

23  
24 Kozanoglu et al. (2022) investigated the long-term effectiveness of combined intermittent  
25 pneumatic compression (IPC) plus low-level laser therapy (LLLT) versus IPC therapy  
26 alone in patients with postmastectomy upper limb lymphedema (PML). The patients were  
27 allocated into two groups in this single-blinded, controlled clinical trial. Group I received  
28 combined treatment with IPC plus LLLT ( $n = 21$ ) and group II received only IPC ( $n = 21$ ).  
29 IPC treatment was given 5 sessions per week for 4 weeks (20 sessions). LLLT was also  
30 performed 5 sessions per week for 4 weeks (20 sessions). Clinical evaluations were  
31 performed before and after the treatment at the 3, 6, and 12-month follow-up visits.  
32 According to within-group analysis, statistically significant improvements in the  
33 circumference difference and grip strength were observed in both groups. Visual analog  
34 scale values for arm pain and shoulder pain during motion were decreased only in group I.  
35 Authors concluded that interventions have positive effects on lymphedema, grip strength,  
36 and pain. Long-term effects of combined therapy, especially on pain, are slightly superior  
37 to the pneumatic compression alone.

38  
39 Wang et al. (2022) analyzed the evidence from existing systematic reviews investigating  
40 the effectiveness and safety of low-level laser therapy (LLLT) in patients with breast  
41 cancer-related lymphedema (BCRL). Conflicting results regarding the effectiveness of  
42 LLLT were presented by the overview of systematic reviews. The AMSTAR 2 showed that

1 the methodological quality of included systematic reviews was low or critically low quality  
 2 due to one or more critical weaknesses. The GRADE and GRADE-CERQual showed that  
 3 the evidence quality was low to very low for most outcomes. The updated systematic  
 4 review showed that LLLT may offer additional benefits as compared to compression  
 5 therapies (pneumatic compression or compression bandage), placebo laser, or no treatment  
 6 for patients with BCRL. However, when compared to other types of active interventions,  
 7 LLLT did not improve outcomes significantly. None of the treatment-related adverse  
 8 events were reported. Many trials had a high or unclear risk of bias for two or more items,  
 9 and this updated systematic review showed low quality of evidence per outcome using  
 10 GRADE approach. Due to insufficient data and poor quality of evidence, there is uncertain  
 11 evidence to reach these conclusions that LLLT is superior to another active or negative  
 12 intervention and is safe. More RCTs of high methodological quality, with large sample  
 13 sizes and long-term follow-up, are needed to inform clinical guidelines and routine  
 14 practice.

15  
 16 Chiu et al. (2023) aimed to organize existing research and determine the optimal  
 17 combination of LLLT parameters for BCRL treatment in a meta-analysis. Although low-  
 18 level laser therapy (LLLT) has been explored as a treatment option for BCRL, they could  
 19 not find a regimen that is more effective than others, which prompted their study. Authors  
 20 focused on the aspects of the treatment area, treatment regimen, and total treatment sessions  
 21 across the included studies. The comparisons between LLLT and non-LLLT were  
 22 performed through a meta-analysis. Post-treatment QOL was significantly better in the  
 23 axillary group. The group treated "three times/week with a laser density of 1.5-2 J/cm<sup>2</sup>"  
 24 had significantly better outcomes in terms of swelling reduction, both immediately post-  
 25 treatment and at 1-3 months follow-ups. The group with > 15 treatment sessions had  
 26 significantly better post-treatment outcomes regarding reduced swelling and improved grip  
 27 strength. According to these results, LLLT can relieve the symptoms of BCRL by reducing  
 28 limb swelling and improving QOL. Further exploration found that a treatment approach  
 29 targeting the axilla, combined with an increased treatment frequency, appropriate laser  
 30 density, and extended treatment course, yielded better outcomes. However, further  
 31 rigorous, large-scale studies, including long-term follow-up, are needed to substantiate this  
 32 regimen.

### 33 34 **Exercise**

35 Kwan et al. (2011) conducted a systematic review of the contemporary literature to distill  
 36 the weight of the evidence and provide recommendations for exercise and lymphedema  
 37 care in breast cancer survivors. Seven studies were identified addressing resistance  
 38 exercise, seven studies on aerobic and resistance exercise, and five studies on other exercise  
 39 modalities. Studies concluded that slowly progressive exercise of varying modalities is not  
 40 associated with the development or exacerbation of breast cancer-related lymphedema and  
 41 can be safely pursued with proper supervision. Combined aerobic and resistance exercise  
 42 appear safe, but confirmation requires larger and more rigorous studies. Authors concluded

1 that strong evidence is now available on the safety of resistance exercise without an  
 2 increase in risk of lymphedema for breast cancer patients. Buchan et al. (2016) compared  
 3 the effect of progressive resistance- or aerobic-based exercise on breast cancer-related  
 4 lymphedema extent and severity, as well as participants' muscular strength and endurance,  
 5 aerobic fitness, body composition, upper-body function and QoL. Authors concluded that  
 6 participating in resistance- or aerobic-based exercise did not change lymphedema status  
 7 but led to clinically relevant improvements in function and QoL, with findings suggesting  
 8 that neither mode is superior with respect to lymphoedema impact. As such, personal  
 9 preferences, survivorship concerns and functional needs are important and  
 10 relevant considerations when prescribing exercise mode to those with secondary  
 11 lymphedema.

12  
 13 Overall, the consensus of managing lymphedema includes an appropriate diagnosis based  
 14 on the patient's history and physical examination and a determination that there  
 15 is consistent evidence to indicate that lymphedema can be reliably measured  
 16 using circumferential measures or volume displacement. Complex decongestive  
 17 therapy is suggested as the main method of conservative care for lymphedema and is a  
 18 combination of therapies that includes manual lymphatic drainage (MLD), application of  
 19 compression low stretch bandages, skin care, education, and exercise. Johansson et al.  
 20 (2015) reported on the evidence-based or traditional treatment of cancer-related  
 21 lymphedema. Authors concluded that with accumulating evidence and experience, it is  
 22 time to consider if altering these treatment principles is needed. Based on accumulating  
 23 evidence, authors suggest less emphasis on manual lymph drainage and more on early  
 24 diagnosis, compression, weight control and exercise for improvement of strength and  
 25 circulation. Bakar and Tuğral (2017) reviewed the current management strategies for lower  
 26 extremity management of lymphedema after gynecologic cancer surgery. Studies indicated  
 27 that the incidence of lower extremity lymphedema ranges between 2.4% and 41% after  
 28 pelvic lymph node dissection in patients with gynecologic malignancies. Thus,  
 29 management of lower extremity lymphedema in patients after gynecologic cancer surgery  
 30 is an important issue. Complex decongestive therapy method is still the gold standard of  
 31 lymphedema management.

32  
 33 Nelson (2017) summarizes the results of recent randomized controlled trials (RCTs)  
 34 investigating the effect of resistance exercise in those with, or at risk for, BCRL. He also  
 35 wanted to determine whether breast cancer survivors can perform RET at sufficient  
 36 intensities to elicit gains in strength without causing BCRL flare-up or incidence. A total  
 37 of 6 RCTs, involving 805 breast cancer survivors, met the inclusion criteria and  
 38 corresponded to the aims of this review. The results of this review indicated that breast  
 39 cancer survivors can perform RET at high-enough intensities to elicit strength gains  
 40 without triggering changes to lymphedema status. There is strong evidence indicating that  
 41 RET produces significant gains in muscular strength without provoking BCRL. Do et al.  
 42 (2017) investigated the effects of a complex rehabilitation (CR) program and complex

1 decongestive therapy (CDT) on edema status, physical function, and quality of life in  
 2 patients with unilateral lower-limb lymphedema after gynecologic cancer surgery. CR  
 3 comprised of stretching, strengthening, and aerobic exercises was performed for 40min,  
 4 five times a week for 4weeks. Intensive CDT was administered by a physical therapist  
 5 during weeks 0-2 and by the patients themselves during weeks 2-4. Results demonstrated  
 6 that the edema status, fatigue, pain, and GCLQ-K scores were significantly improved in  
 7 both groups after the 4-week intervention. Physical function and fatigue and the 30-s chair  
 8 stand test and quadriceps muscle strength were significantly improved in the CRCDT  
 9 group compared with the CDT alone group. Authors concluded that CR improves physical  
 10 function, fatigue, and muscular strength without increasing edema status in patients with  
 11 unilateral lower-limb lymphedema after gynecologic cancer surgery. Yeung et al. (2018)  
 12 conducted a systematic review and meta-analysis on aquatic therapy compared to other  
 13 lymphedema interventions. Four RCTs of moderate quality were included. There was  
 14 moderate level evidence of no significant short-term differences in lymphedema status  
 15 (relative volume) between patients receiving aquatic lymphatic therapy compared to land  
 16 based standard care. There was low level evidence that no significant difference between  
 17 aquatic lymphatic therapy and standard care for improving upper limb physical function.  
 18 Authors conclude that current evidence indicates no significant benefit of aquatic  
 19 lymphatic therapy over standard land-based care for treatment of lymphedema. Further  
 20 research is needed to strengthen the evidence.

21  
 22 Baumann et al. (2018) assessed the effect of different types of exercise on breast cancer-  
 23 related lymphedema (BCRL) in order to understand the role of exercise in this patient  
 24 group. Eleven randomized controlled trials that included 458 women with breast cancer in  
 25 aftercare were included. The different types of exercise consisted of aqua lymph training,  
 26 swimming, resistance exercise, yoga, aerobic, and gravity-resistive exercise. Four of the  
 27 studies measured a significant reduction in BCRL status based on arm volume and seven  
 28 studies reported significant subjective improvements. No study showed adverse effects of  
 29 exercise on BCRL. Authors concluded that the evidence indicates that exercise can  
 30 improve subjective and objective parameters in BCRL patients, with dynamic, moderate,  
 31 and high-frequency exercise appearing to provide the most positive effects. Hasenoehrl et  
 32 al. (2020) performed a systematic review analyzing resistance exercise (RE) intervention  
 33 trials in breast cancer survivors (BCS) regarding their effect on breast cancer-related  
 34 lymphedema (BCRL) status. Authors concluded that RE seems to be a safe exercise  
 35 intervention for BCS and not to be harmful concerning the risk of lymphedema.  
 36 Lymphedema assessment methods that allow for a qualitative analysis of arm tissue  
 37 composition should be favored. At the current time breast cancer related lymphedema is  
 38 incurable but well manageable by a number of physical therapy modalities, especially  
 39 complete decongestive therapy (CDT). One of the encouraging treatment methods is  
 40 resistance exercise.

1 Kilbreath et al. (2020) investigated whether an exercise program reduced breast  
 2 lymphoedema symptoms compared to a non-exercise control group. This single-blinded  
 3 randomized controlled trial was conducted in which women with stable breast  
 4 lymphoedema ( $n = 89$ ) were randomized into an exercise ( $n = 41$ ) or control ( $n = 47$ ) group.  
 5 The intervention comprised a 12-week combined aerobic and resistance training program,  
 6 supervised weekly by an accredited exercise physiologist. All participants completed a  
 7 weekly symptoms diary and were assessed monthly to ensure that there was no  
 8 exacerbation of their lymphoedema. Changes in the breast were captured physically with  
 9 ultrasound and bioimpedance spectroscopy and changes in symptoms were captured using  
 10 European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer  
 11 (BR23) and Lymphoedema Symptom Intensity and Distress questionnaires. The exercise  
 12 group reported a greater reduction in breast-related symptoms than the control group,  
 13 assessed by the EORTC BR23 breast symptom questions. Measures of extracellular fluid,  
 14 assessed with bioimpedance spectroscopy ratio, decreased in the exercise group compared  
 15 to the control group. No significant difference was detected in dermal thickness in the  
 16 breast, assessed by ultrasound. Session attendance in the exercise sessions was high, with  
 17 two musculoskeletal adverse events reported, but no exacerbations of lymphoedema  
 18 observed. Authors concluded that combined resistance and aerobic exercise training is safe  
 19 for women living with breast lymphoedema. Preliminary data suggest exercise training can  
 20 reduce breast lymphoedema symptoms to a greater extent than usual care.

21  
 22 Saraswathi et al. (2021) systematically reviewed the effect of yoga therapy on managing  
 23 lymphedema, increasing the range of motion (ROM), and quality of life (QoL) among  
 24 breast cancer survivors. Studies which assessed the outcome variables such as QoL and  
 25 management of lymphedema or related physical symptoms as effect of yoga intervention  
 26 were considered for review. The different styles of yoga employed in the studies were  
 27 Iyengar yoga ( $n = 2$ ), Satyananda yoga ( $n = 2$ ), Hatha yoga ( $n = 2$ ), and Ashtanga yoga  
 28 ( $n = 1$ ). The length of intervention and post intervention analysis ranged from 8 weeks to  
 29 12 months. Authors concluded that yoga could be a safe and feasible exercise intervention  
 30 for BCRL patients. Evidence generated from these studies was of moderate strength.  
 31 Further long-term clinical trials with large sample size are essential for the development  
 32 and standardization of yoga intervention guidelines for BCRL patients.

33  
 34 Bruce et al. (2021) evaluated whether a structured exercise program improved functional,  
 35 and health related quality of life outcomes compared with usual care for women at high  
 36 risk of upper limb disability after breast cancer surgery. Subjects included 392 women  
 37 undergoing breast cancer surgery, at risk of postoperative upper limb morbidity,  
 38 randomized (1:1) to usual care with structured exercise ( $n=196$ ) or usual care alone  
 39 ( $n=196$ ). Usual care (information leaflets) only or usual care plus a physiotherapy led  
 40 exercise program, incorporating stretching, strengthening, physical activity, and behavioral  
 41 change techniques to support adherence to exercise, introduced at 7-10 days  
 42 postoperatively, with two further appointments at one and three months. Main outcome

1 measures included the Disability of Arm, Hand, and Shoulder (DASH) questionnaire at 12  
 2 months, analyzed by intention to treat. Secondary outcomes included DASH subscales,  
 3 pain, complications, health related quality of life, and resource use, from a health and  
 4 personal social services perspective. Upper limb function improved after exercise  
 5 compared with usual care for exercise. Secondary outcomes favored exercise over usual  
 6 care, with lower pain intensity at 12 months and fewer arm disability symptoms at 12  
 7 months. No increase in complications, lymphoedema, or adverse events was noted in  
 8 participants allocated to exercise. Exercise accrued lower costs per patient and was cost  
 9 effective compared with usual care. Authors concluded that the PROSPER exercise  
 10 program was clinically effective and cost effective and reduced upper limb disability one  
 11 year after breast cancer treatment in patients at risk of treatment related postoperative  
 12 complications.

13  
 14 Corum et al. (2021) compared the effects of complex decongestive therapy (CDT)  
 15 accompanied by resistance exercises on extremity circumference, lymphedema volume,  
 16 grip strength, functional status, and quality of life in the treatment of breast cancer-related  
 17 lymphedema (BCRL) in patients with and without pain. Fifty patients with unilateral  
 18 BCRL were divided into groups: with pain (Group 1,  $n = 25$ ) and without pain (Group 2,  
 19  $n = 25$ ). Thirty minutes of manual lymphatic drainage and multilayered short-stretch  
 20 bandaging were applied to all patients five times a week for 4 weeks. In addition, all  
 21 patients were informed about skin care and given a supervised resistance exercise program  
 22 throughout the treatment. During the 1-month follow-up period, patients were asked to use  
 23 low-tension elastic garments and to continue their home exercise program. Differences in  
 24 upper extremity circumference and volume; grip strength; Quick Disabilities of the Arm,  
 25 Shoulder, and Hand; and Functional Assessment of Cancer Therapy-Breast scores were  
 26 evaluated at baseline, after treatment (week 4), and at 1-month follow-up. Moreover, the  
 27 pain intensity of patients in Group 1 was measured using the visual analog scale (VAS).  
 28 Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome  
 29 measures after treatment and at follow-up ( $p < 0.05$ ); however, no significant difference  
 30 was observed between the groups ( $p > 0.05$ ). In Group 1, a statistically significant decrease  
 31 was observed in the VAS score both at the end of treatment and at 1-month follow-up ( $p <$   
 32  $0.05$ ). Authors concluded that combined CDT and resistance exercises appear to be  
 33 effective in BCRL patients both with and without pain.

34  
 35 Hayes et al. (2022) evaluated the effects of exercise on (i) the prevention of cancer-related  
 36 lymphedema (CRL), and (ii) the treatment of CRL, lymphedema-associated symptoms,  
 37 and other health outcomes among individuals with CRL in a systematic review and meta-  
 38 analysis. Twelve studies ( $n = 1,955$ ; 75% moderate-high quality) and 36 studies ( $n = 1,741$ ;  
 39 58% moderate-high quality) were included in the prevention and treatment aim,  
 40 respectively. Relative risk of developing CRL for those in the exercise group compared  
 41 with the non-exercise group was 0.90 overall, and 0.49 for those with 5 or more lymph  
 42 nodes removed. Improvements post-intervention were observed for pain, upper-body

1 function and strength, lower-body strength, fatigue and quality of life for those in the  
2 exercise group. Authors concluded that findings support the application of exercise  
3 guidelines for the wider cancer population to those with or at risk of CRL. This includes  
4 promotion of aerobic and resistance exercise, and not just resistance exercise alone, as well  
5 as unsupervised exercise guided by symptom response.

6  
7 Maccarone et al. (2023) evaluated the effects of water-based exercise on pain, limb motor  
8 function, quality of life (QoL), and limb volume among patients affected by primary and  
9 secondary upper and lower limb lymphedema. The search produced a total of 88 studies.  
10 Eight randomized controlled trials and one clinical study of patients with primary or  
11 secondary lymphedema of upper or lower limbs who had undergone water-based treatment  
12 were included in the present study. Most trials had focused on breast cancer-related  
13 lymphedema. The shoulder range of flexion, external rotation, and abduction have been  
14 shown to improve after performing a water-based exercise protocol. Some evidence has  
15 also demonstrated that the lymphedematous limb strength can improve. Moreover, water-  
16 based exercise seemed to improve pain perception and QoL for patients with upper or lower  
17 limb lymphedema. In contrast, in the control groups, the QoL showed a tendency to worsen  
18 over time. Although some studies had not reported beneficial effects on the  
19 lymphedematous limb volume, most of the studies examined had reported a reduction in  
20 volume, especially in the short term. No adverse events were reported in the included  
21 studies. Authors concluded that these findings from the present review have shown the  
22 potential for aquatic exercise in lymphedema management. However, at the same time, the  
23 findings underline the multiple limitations resulting from the heterogeneity in the study  
24 populations and related physical activity protocols. The role of aquatic exercise in the  
25 conservative treatment of lymphedema requires further investigation in the future to define  
26 specific protocols of application.

27  
28 Lin et al. (2023) sought to determine the effective exercise methods for different  
29 complications of breast cancer patients after surgery in a systematic review and meta-  
30 analysis. Aerobic exercise reduced the intensity of the pain, improved shoulder flexion and  
31 internal rotation range, lessened upper limb dysfunction and improved muscle strength  
32 during flexion and abduction. Shoulder elbow movement improved the range of shoulder  
33 external rotation and reduced the incidence of arm lymphedema. Anti-resistance exercise  
34 also lessened upper limb dysfunction. Wang et al. (2023) This examined the existing best  
35 evidence on resistance exercise for BCRL to accurately describe the current status of the  
36 field and offer recommendations for clinicians in a systematic, evidence-based review.  
37 Twenty-two articles (7 guidelines, 4 consensus documents and 11 systematic reviews) were  
38 included. Six clinical topics involving 43 recommendations were identified.  
39 Recommendations were categorized by safety of resistance training, effectiveness of  
40 resistance training, evaluation prior to resistance exercise, resistance exercise prescription,  
41 resistance training outcome index and points for attention. Based on the available research,  
42 there is strong evidence evaluating the safety of resistance exercise. The findings support

1 the assertion that breast cancer patients at risk of or with lymphoedema should be  
2 encouraged to do resistance exercise. Resistance exercise could improve patients' muscle  
3 strength and quality of life. Authors also summarized the evidence of resistance exercise  
4 prescription which can be used to guide clinical practice. However, there are some  
5 inconsistent recommendations in the review, such as the effects of resistance exercise on  
6 preventing and relieving lymphoedema. The main heterogeneity comes from different  
7 exercise prescriptions in terms of exercise type, frequency, intensity, etc. Future studies are  
8 needed to provide high-quality evidence for the specificity of exercise prescription, to  
9 identify the appropriate exercise volume for patients at different stages of lymphoedema or  
10 at risk of lymphoedema. In terms of whether or not to wear compression garments during  
11 exercise, future studies need to focus on patient comfort and compliance with these during  
12 exercise: clinicians should not simply take the effects of relieving lymphoedema into  
13 consideration.

14  
15 Hsu et al. (2024) investigated the effectiveness of physical activity in alleviating lower  
16 limb lymphedema among patients with gynecological cancer after surgery in a systematic  
17 review. Seven studies (5 randomized controlled trials) containing 261 subjects were  
18 synthesized. The exercise interventions for lower limb lymphedema included active,  
19 aerobic, aquatic, and weight-lifting exercises. Meta-analyses showed that active exercise  
20 had no effect on lymphedema symptoms of limb volume, pain, and heaviness. However,  
21 the effectiveness of exercise on limb volume had subthreshold borderline significance in 2  
22 studies. Three studies found that lymphedema symptoms were significantly improved after  
23 exercise interventions. The adherence rate of the exercise was 77-100%, with the only  
24 complication being cellulitis. Authors concluded that although the meta-analysis does not  
25 reveal a significant effect, the systematic review study demonstrated that exercise is  
26 feasible, safe, and has a clinical effect on alleviating lymphedema-related symptoms of  
27 women following gynecological cancer surgery.

28  
29 Wittenkamp et al. (2025) summarized the evidence of the immediate and long-term effect  
30 of exercise interventions in patients with either primary or secondary lower limb  
31 lymphedema (LLL) on health-related quality of life (HR-QOL), physical function, self-  
32 reported symptoms, lower limb volume, and adverse events. Prospective exercise trials  
33 investigating exercise interventions as a single- or multicomponent program in patients  
34 with LLL including assessment of at least one of the following outcomes: HR-QOL, self-  
35 reported LLL symptoms (heaviness, tension, and pain), physical function, or lower limb  
36 volume. Randomized controlled trials (RCTs), single-group studies, and cross-over trials  
37 were eligible. Twelve studies were included: three RCTs, five single-group studies, and  
38 four cross-over trials with a total of three hundred and sixty-seven participants. In patients  
39 with LLL, irrespective of severity, exercise seemed to have small but positive effects on  
40 HR-QOL, physical function, pain, and lower limb volume. Quality assessment showed  
41 high risk of bias. Large heterogeneity in participants, interventions, and outcome measures  
42 hinders performing of meta-analyses. Authors concluded that based on a small number of

1 studies with large clinical heterogeneity, poor methodological quality, hence low level of  
2 certainty of evidence, it was not possible to provide evidence-based recommendations on  
3 exercise for patients with LLL.

4  
5 Wang et al. (2025) examined how resistance training affects lymphedema and muscle  
6 strength; and evaluated the extent of improvement in lymphedema with different exercise  
7 dosages in breast cancer patients in a meta-analysis. Thirty studies were synthesized in the  
8 systematic review. Resistance training was found to reduce lymphedema and significantly  
9 enhance upper and lower limb muscle strength. High-intensity training [5 ~ 8 repetition  
10 maximum (RM)] with a frequency of four times per week and a duration of 120~180 min  
11 per week showed a larger effect on lymphedema compared to moderate- to low-intensity  
12 training (8 ~ 20 RM) with three or fewer sessions per week and a duration of up to 120  
13 min. Additionally, exercise programs lasting 12 weeks were more effective than those  
14 lasting less than 12 weeks. Authors concluded that high-intensity resistance training is  
15 more effective than low-intensity training in reducing lymphedema and enhancing muscle  
16 strength. Breast cancer patients with lower tolerance to exercise intensity can achieve  
17 maximal benefits in improving lymphedema by appropriately increasing the frequency and  
18 duration of exercise. Additionally, patients are encouraged to exercise for at least 12 weeks  
19 to ensure the effects.

20  
21 Xue et al. (2025) evaluated the effects of exercise interventions on pain, lymphedema,  
22 shoulder joint range of motion (ROM), muscle strength, and quality of life in postoperative  
23 breast cancer patients, and to provide evidence-based recommendations for clinical  
24 practice in a systematic review and meta-analysis. A total of 22 randomized controlled  
25 trials with 2,305 patients were included in the meta-analysis. Exercise interventions  
26 significantly reduced postoperative pain and improved muscle strength across various  
27 muscle groups. Exercise was also effective in reducing the incidence of lymphedema and  
28 improving shoulder ROM, particularly in flexion, extension, abduction, and adduction. In  
29 terms of quality of life, exercise enhanced physical function, role function, and emotional  
30 well-being, and reduced fatigue and appetite loss. Authors concluded that exercise  
31 interventions are beneficial for improving pain management, lymphedema control, upper  
32 limb function, muscle strength, and overall quality of life in postoperative breast cancer  
33 patients. These findings support the inclusion of exercise as a key component of  
34 postoperative rehabilitation. Future research should focus on optimizing exercise protocols  
35 and exploring long-term effects on breast cancer survivors.

36  
37 García-Chico et al. (2026) summarized the current evidence on the impact of exercise in  
38 patients at risk or with breast cancer-related lymphedema (BCRL) through an umbrella  
39 review of existing meta-analysis and a systematic review and meta-analysis of randomized  
40 controlled trials (RCTs). Three systematic reviews including 14 individual meta-analyses  
41 were included in the umbrella review. Two of these met the criteria of strong evidence,  
42 reporting beneficial effects of exercise on upper- and lower-body strength. A total of 46

1 RCTs were included in the systematic review, of which 11 could be meta-analyzed. Strong  
2 evidence was found for a beneficial effect of exercise on upper- and lower-body strength  
3 and upper-limb disability. Strong evidence supports the beneficial effects of exercise on  
4 upper- and lower-body strength and upper-limb disability in patients at risk or with BCRL.

### 5 6 **Measurement of Lymphedema**

7 Hidding et al. (2016) attempted to provide best evidence of which measurement  
8 instruments are most appropriate in measuring lymphedema in its different stages. Authors  
9 concluded that measurement instruments with evidence for good reliability and validity are  
10 Bioelectrical Impedance Spectroscopy (BIS), water volumetry, tape measurement and  
11 perometry, where BIS can detect alterations in extracellular fluid in stage 1 lymphedema  
12 and the other measurement instruments alterations in volume starting from stage 2. In  
13 research water volumetry is indicated as reference test for measuring lymphedema in upper  
14 extremities. Limitations included the following: no uniform definition of lymphedema was  
15 available and a gold standard as reference test was lacking. Items concerning risk of bias  
16 were study design, patient selection, description of lymphedema, blinding of test outcomes  
17 and number of included patients.

18  
19 Şahinoğlu et al. (2024) evaluated the agreement between the American Physical Therapy  
20 Association (APTA) criteria, the criteria of Ramos et al., and the International Society of  
21 Lymphology (ISL) criteria in patients with upper and lower extremity lymphedema.  
22 Several classification systems are used to grade the severity of lymphedema. Their  
23 agreement with each other has not been reported. A total of 156 patients (63 and 93 patients  
24 with upper and lower extremity lymphedema, respectively) were included. The  
25 circumference measurements and limb volume were measured. The severity of  
26 lymphedema of the patients was classified as mild, moderate, and severe lymphedema  
27 using the APTA criteria, the criteria of Ramos et al., and the ISL criteria. An acceptable  
28 and poor agreement were found between the criteria in upper and lower extremity  
29 lymphedema, respectively. In pairwise comparisons, an acceptable agreement was found  
30 among each comparison in upper extremity lymphedema, and a poor agreement was found  
31 among each comparison in lower extremity lymphedema except between the APTA criteria  
32 and the criteria of Ramos et al. Authors concluded that patients with upper extremity  
33 lymphedema classified according to these criteria can be assumed to be samples of the  
34 same population; however, patients with lower extremity lymphedema graded according  
35 to the ISL criteria may be included in a different classification when they grade with the  
36 APTA criteria and the criteria of Ramos et al.

### 37 38 ***PRACTITIONER SCOPE AND TRAINING***

39 Practitioners should practice only in the areas in which they are competent based on their  
40 education, training, and experience. Levels of education, experience, and proficiency may  
41 vary among individual practitioners. It is ethically and legally incumbent on a practitioner

1 to determine where they have the knowledge and skills necessary to perform such services  
2 and whether the services are within their scope of practice.

3  
4 It is best practice for the practitioner to appropriately render services to a member only if  
5 they are trained, equally skilled, and adequately competent to deliver a service compared  
6 to others trained to perform the same procedure. If the service would be most competently  
7 delivered by another health care practitioner who has more skill and training, it would be  
8 best practice to refer the member to the more expert practitioner.

9  
10 Best practice can be defined as a clinical, scientific, or professional technique, method, or  
11 process that is typically evidence-based and consensus driven and is recognized by a  
12 majority of professionals in a particular field as more effective at delivering a particular  
13 outcome than any other practice (Joint Commission International Accreditation Standards  
14 for Hospitals, 2020).

15  
16 Depending on the practitioner’s scope of practice, training, and experience, a member’s  
17 condition and/or symptoms during examination or the course of treatment may indicate the  
18 need for referral to another practitioner or even emergency care. In such cases it is prudent  
19 for the practitioner to refer the member for appropriate co-management (e.g., to their  
20 primary care physician) or if immediate emergency care is warranted, to contact 911 as  
21 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice  
22 guideline for information.

### 23 24 **REFERENCES**

25 Ahmed Omar MT, Abd-El-Gayed Ebid A, El Morsy AM. Treatment of post-mastectomy  
26 lymphedema with laser therapy: double blind placebo control randomized study. *J Surg*  
27 *Res.* 2011;165(1):82-90

28  
29 Andersen L, Højris I, Erlandsen M, Andersen J. Treatment of breast-cancer-related  
30 lymphedema with or without manual lymphatic drainage—a randomized study. *Acta*  
31 *Oncol (Stockh).* 2000;39(3):399-405

32  
33 Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling  
34 lymphoedema of the limbs. *Cochrane Database Syst Rev.* 2004;(4):CD003141

35  
36 Bakar Y, Tuğral A. Lower Extremity Lymphedema Management after Gynecologic Cancer  
37 Surgery: A Review of Current Management Strategies. *Ann Vasc Surg.* 2017;44:442-  
38 450

39  
40 Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, Newton RU,  
41 Galvao DA. Effects of physical exercise on breast cancer-related secondary  
42 lymphedema: a systematic review. *Breast Cancer Res Treat.* 2018 Jul;170(1):1-13

- 1 Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, Tumilty S. Low level  
2 laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a  
3 systematic review. *BMC Cancer*. 2017 Dec 7;17(1):833  
4
- 5 Białoszewski D, Woźniak W, Zarek S. Clinical efficacy of kinesiology taping in reducing  
6 edema of the lower limbs in patients treated with the Ilizarov method—preliminary  
7 report. *Ortop Traumatol Rehabil*. 2009;11(1):46-54  
8
- 9 Bicego D, Brown K, Ruddick M, Storey D, Wong C, Harris SR. Exercise for women with  
10 or at risk for breast cancer-related lymphedema. *Phys Ther*. 2006;86(10):1398-1405  
11
- 12 Borman P, Yaman A, Yasrebi S, Pınar İnanlı A, Arıkan Dönmez A. Combined Complete  
13 Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional  
14 Status in Patients With Breast Cancer-Related Lymphedema. *Clin Breast Cancer*.  
15 2022;22(3):e270-e277. doi:10.1016/j.clbc.2021.08.005  
16
- 17 Bosman J. Lymph taping for lymphoedema: an overview of the treatment and its uses. *Br J*  
18 *Community Nurs*. 2014;Suppl:S12-S18  
19
- 20 Buchan J, Janda M, Box R, Schmitz K, Hayes S. A randomized trial on the effect of  
21 exercise mode on breast cancer-related lymphedema. *Med Sci Sports Exerc*.  
22 2016;48(10):1866-1874  
23
- 24 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology  
25 Inquiry Service. Manual lymph drainage or intermittent pneumatic compression for  
26 adult patients with secondary lymphedema: clinical effectiveness. *Health Technol*  
27 *Assess*. 2010. Accessed March 8, 2026  
28
- 29 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology  
30 Inquiry Service. Compression Garments for the Treatment of Primary and Secondary  
31 Lymphedema: Clinical Effectiveness and Guidelines. 2011. Accessed March 8, 2026  
32
- 33 Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy  
34 lymphedema with low-level laser therapy: a double blind, placebo-controlled trial.  
35 *Cancer*. 2003;98(6):1114-1122  
36
- 37 Casley-Smith JR, Boris M, Weindorf S, Lasinski B. Treatment for lymphedema of the  
38 arm—the Casley-Smith method: a noninvasive method produces continued reduction.  
39 *Cancer*. 1998;83(12 Suppl American):2843-2860  
40
- 41 Chaput G, Ibrahim M. Cancer-related lymphedema. *Can Fam Physician*. 2023;69(10):691-  
42 695

- 1 Cheifetz O, Haley L; Breast Cancer Action. Management of secondary lymphedema  
2 related to breast cancer. *Can Fam Physician*. 2010;56(12):1277-1284  
3
- 4 Cheng JT, Leite VF, Tennison JM, Gutierrez C, Kline-Quiroz C, Capozzi LC, Yu S, Krause  
5 KJ, Langelier D, Parke SC. Rehabilitation Interventions for Head and Neck Cancer-  
6 Associated Lymphedema: A Systematic Review. *JAMA Otolaryngol Head Neck Surg*.  
7 2023 Aug 1;149(8):743-753  
8
- 9 Cheng H, Gong J, Yu L, et al. Compression sleeves for prevention and treatment of breast  
10 cancer-related lymphedema: a systematic review and meta-analysis. *Breast Cancer Res*  
11 *Treat*. 2025;215(1):41. Published 2025 Dec 13. doi:10.1007/s10549-025-07846-9  
12
- 13 Cheville AL, McLaughlin SA, Glaser GE, Boughey JC. Cancer related lymphedema. *BMJ*.  
14 2025;390:10.1136/bmj-2024-081351. Published 2025 Jul 3. doi:10.1136/bmj-2024-  
15 081351  
16
- 17 Chiu ST, Lai UH, Huang YC, Leong CP, Chen PC. Effect of various photobiomodulation  
18 regimens on breast cancer-related lymphedema: A systematic review and meta-  
19 analysis. *Lasers Med Sci*. 2023 Dec 22;39(1):11  
20
- 21 Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema  
22 beyond breast cancer: a systematic review and meta-analysis of cancer-related  
23 secondary lymphedema. *Cancer*. 2010;116(22):5138–5149.  
24 <https://doi.org/10.1002/cncr.25458>  
25
- 26 Corum M, Basoglu C, Korkmaz MD, Yildirim MA, Ones K. Effectiveness of Combined  
27 Complex Decongestive Therapy and Resistance Exercises in the Treatment of  
28 Lymphedema Associated with Breast Cancer and the Effect of Pain on Treatment  
29 Response. *Lymphat Res Biol*. 2021;19(4):383-390. doi:10.1089/lrb.2020.0099  
30
- 31 Dayes IS, Whelan TJ, Julian JA, Parpia S, Pritchard KI, D'Souza DP, Kligman L, Reise D,  
32 LeBlanc L, McNeely ML, Manchul L, Wiernikowski J, Levine MN. Randomized trial  
33 of decongestive lymphatic therapy for the treatment of lymphedema in women with  
34 breast cancer. *J Clin Oncol*. 2013;31(30):3758–3763.  
35 <https://doi.org/10.1200/JCO.2012.45.7192>  
36
- 37 de-la-Cruz-Fernández L, Galiano-Castillo N, Galván-Banqueri P, et al. Lymphedema  
38 management in patients with head and neck cancer: a systematic review of randomized  
39 controlled trials on physical therapy interventions. *Support Care Cancer*.  
40 2025;33(5):420. Published 2025 Apr 26. doi:10.1007/s00520-025-09438-1

- 1 De Vrieze T, Gebruers N, Nevelsteen I, et al. Manual lymphatic drainage with or without  
2 fluoroscopy guidance did not substantially improve the effect of decongestive  
3 lymphatic therapy in people with breast cancer-related lymphoedema (EForT-BCRL  
4 trial): a multicentre randomised trial. *J Physiother.* 2022;68(2):110-122.  
5 doi:10.1016/j.jphys.2022.03.010  
6
- 7 Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens MR. Different physical  
8 treatment modalities for lymphoedema developing after axillary lymph node dissection  
9 for breast cancer: a review. *Eur J Obstet Gynecol Reprod Biol.* 2010;149(1):3–9  
10
- 11 Didem K, Ufuk YS, Serdar S, Zümre A. The comparison of two different physiotherapy  
12 methods in treatment of lymphedema after breast surgery. *Breast Cancer Res Treat.*  
13 2005;93(1):49–54  
14
- 15 Dirican A, Andacoglu O, Johnson R, McGuire K, Mager L, Soran A. The short-term effects  
16 of low-level laser therapy in the management of breast-cancer-related lymphedema.  
17 *Support Care Cancer.* 2011;19(5):685–690. [https://doi.org/10.1007/s00520-010-0888-](https://doi.org/10.1007/s00520-010-0888-8)  
18 8  
19
- 20 Do JH, Choi KH, Ahn JS, Jeon JY. Effects of a complex rehabilitation program on edema  
21 status, physical function, and quality of life in lower-limb lymphedema after  
22 gynecological cancer surgery. *Gynecol Oncol.* 2017;147(2):450–455.  
23 <https://doi.org/10.1016/j.ygyno.2017.09.003>  
24
- 25 Donahue PMC, MacKenzie A, Filipovic A, Koelmeyer L. Advances in the prevention and  
26 treatment of breast cancer-related lymphedema. *Breast Cancer Res Treat.* 2023  
27 Jul;200(1):1-14  
28
- 29 Executive Committee. The diagnosis and treatment of peripheral lymphedema: 2016  
30 consensus document of the International Society of Lymphology. *Lymphology.*  
31 2016;49(4):170–184  
32
- 33 Executive Committee of the International Society of Lymphology. The diagnosis and  
34 treatment of peripheral lymphedema: 2020 Consensus Document of the International  
35 Society of Lymphology. *Lymphology* 2020, 53, 3–19  
36
- 37 Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, Bao T, Bily L,  
38 Tuppo CM, Williams AF, Karadibak D. Manual lymphatic drainage for lymphedema  
39 following breast cancer treatment. *Cochrane Database Syst Rev.* 2015;(5):CD003475  
40
- 41 Finnane A, Janda M, Hayes SC. Review of the evidence of lymphedema treatment effect.  
42 *Am J Phys Med Rehabil.* 2015;94(6):483–488

- 1 Földi E. The treatment of lymphedema. *Cancer*. 1998;83(12 Suppl American):2833–2834  
2
- 3 Forner-Cordero I, Muñoz-Langa J, DeMiguel-Jimeno JM, Rel-Monzó P. Physical  
4 therapies in the decongestive treatment of lymphedema: A randomized, non-inferiority  
5 controlled study. *Clin Rehabil*. 2021;35(12):1743-1756.  
6 doi:10.1177/02692155211032651  
7
- 8 Fu, Mei R et al. Putting evidence into practice: cancer-related lymphedema. *Clinical*  
9 *journal of oncology nursing* vol. 18 Suppl (2014): 68-79. doi:10.1188/14.CJON.S3.68-  
10 79  
11
- 12 García-Chico C, López-Ortiz S, Lorenzo-Crespo C, Pinto-Fraga J, Santos-Lozano A,  
13 Domínguez-García A. Wrapping up the evidence: bandaging in breast cancer-related  
14 lymphedema-a systematic review and meta-analysis. *Breast Cancer*. 2025;32(4):654-  
15 675. doi:10.1007/s12282-025-01693-8  
16
- 17 García-Chico C, López-Ortiz S, Pinto-Fraga J, et al. Physical exercise and breast cancer-  
18 related lymphedema: an umbrella review, systematic review and meta-analysis. *Disabil*  
19 *Rehabil*. 2026;48(2):259-275. doi:10.1080/09638288.2025.2536722  
20
- 21 Gatt M, Willis S, Leuschner S. A meta-analysis of the effectiveness and safety of  
22 kinesiology taping in the management of cancer-related lymphoedema. *Eur J Cancer*  
23 *Care*. 2017;26(5):e12510  
24
- 25 Gilchrist L, Levenhagen K, Davies CC, Koehler L. Effectiveness of complete decongestive  
26 therapy for upper extremity breast cancer-related lymphedema: a review of systematic  
27 reviews. *Med Oncol*. 2024;41(11):297. Published 2024 Oct 23  
28
- 29 Golshan M, Smith B. Prevention and management of arm lymphedema in the patient with  
30 breast cancer. *J Support Oncol*. 2006;4(8):381–386  
31
- 32 Haghghat S, Lotfi-Tokaldany M, Yunesian M, Akbari ME, Nazemi F, Weiss J. Comparing  
33 two treatment methods for post mastectomy lymphedema: complex decongestive  
34 therapy alone and in combination with intermittent pneumatic compression.  
35 *Lymphology*. 2010;43(1):25–33  
36
- 37 Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in  
38 patients with breast cancer. *Ann Surg Oncol*. 2007;14(6):1904–1908  
39
- 40 Harris SR, Hugi MR, Olivotto IA, Levine M; Steering Committee for Clinical Practice  
41 Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines

- 1 for the care and treatment of breast cancer: 11. Lymphedema. *CMAJ*.  
2 2001;164(2):191–199  
3
- 4 Hasenoehrl T, Keilani M, Palma S, Crevenna R. Resistance exercise and breast cancer  
5 related lymphedema - a systematic review update. *Disabil Rehabil*. 2020 Jan;42(1):26-  
6 35  
7
- 8 Hayes SC, Singh B, Reul-Hirche H, et al. The Effect of Exercise for the Prevention and  
9 Treatment of Cancer-related Lymphedema: A Systematic Review with Meta-analysis  
10 [published online ahead of print, 2022 Mar 22]. *Med Sci Sports Exerc*.  
11 2022;10.1249/MSS.0000000000002918  
12
- 13 Hidding JT, Viehoff PB, Beurskens CH, van Laarhoven HW, Nijhuis-van der Sanden MW,  
14 van der Wees PJ. Measurement properties of instruments for measuring lymphedema:  
15 systematic review. *Phys Ther*. 2016;96(12):1965–1981  
16
- 17 Hsu YY, Nguyen TT, Chou YJ, Ho CL. Effects of exercise on lower limb lymphedema in  
18 gynecologic cancer: A systematic review and meta-analysis. *Eur J Oncol Nurs*.  
19 2024;70:102550  
20
- 21 Hwang JM, Hwang JH, Kim TW, Lee SY, Chang HJ, Chu IH. Long-term effects of  
22 complex decongestive therapy in breast cancer patients with arm lymphedema after  
23 axillary dissection. *Ann Rehabil Med*. 2013;37(5):690–697  
24
- 25 Johansson K, Karlsson K, Nikolaidis P. Evidence-based or traditional treatment of cancer-  
26 related lymphedema. *Lymphology*. 2015;48(1):24–27  
27
- 28 Kalemikerakis I, Evaggelakou A, Kavga A, Vastardi M, Konstantinidis T, Govina O.  
29 Diagnosis, treatment and quality of life in patients with cancer-related lymphedema. *J*  
30 *BUON*. 2021;26(5):1735-1741  
31
- 32 Kalron A, Bar-Sela S. A systematic review of the effectiveness of Kinesio Taping--fact or  
33 fashion?. *Eur J Phys Rehabil Med*. 2013;49(5):699–709  
34
- 35 Karadibak D, Yavuzsen T, Saydam S. Prospective trial of intensive decongestive  
36 physiotherapy for upper extremity lymphedema. *J Surg Oncol*. 2008;97(7):572–577  
37
- 38 Kärki A, Anttila H, Tasmuth T, Rautakorpi UM. Lymphoedema therapy in breast cancer  
39 patients: a systematic review on effectiveness and a survey of current practices and  
40 costs in Finland. *Acta Oncol*. 2009;48(6):850–859

- 1 Kasseroller RG. The Vodder School: the Vodder method. *Cancer*. 1998;83(12 Suppl  
2 American):2840–2842  
3
- 4 Kilbreath SL, Ward LC, Davis GM, Degnim AC, Hackett DA, Skinner TL, Black D.  
5 Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled  
6 exercise trial. *Breast Cancer Res Treat*. 2020;184(2):459–467. doi:10.1007/s10549-  
7 020-05863-4  
8
- 9 Kim SJ, Park YD. Effects of complex decongestive physiotherapy on the oedema and the  
10 quality of life of lower unilateral lymphoedema following treatment for gynecological  
11 cancer. *Eur J Cancer Care (Engl)*. 2008;17(5):463–468  
12
- 13 Kim DS, Sim YJ, Jeong HJ, Kim GC. Effect of active resistive exercise on breast cancer-  
14 related lymphedema: a randomized controlled trial. *Arch Phys Med Rehabil*.  
15 2010;91(12):1844–1848  
16
- 17 Kligman L, Wong RK, Johnston M, Laetsch NS. The treatment of lymphedema related to  
18 breast cancer: a systematic review and evidence summary. *Support Care Cancer*.  
19 2004;12(6):421–431  
20
- 21 Koul R, Dufan T, Russell C, Guenther W, Nugent Z, Sun X, Cooke AL. Efficacy of  
22 complete decongestive therapy and manual lymphatic drainage on treatment-related  
23 lymphedema in breast cancer. *Int J Radiat Oncol Biol Phys*. 2007;67(3):841–846  
24
- 25 Kozanoglu E, Basaran S, Paydas S, Sarpel T. Efficacy of pneumatic compression and low-  
26 level laser therapy in the treatment of postmastectomy lymphoedema: a randomized  
27 controlled trial. *Clin Rehabil*. 2009;23(2):117–124  
28
- 29 Kozanoglu E, Gokcen N, Basaran S, Paydas S. Long-Term Effectiveness of Combined  
30 Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with  
31 Postmastectomy Lymphedema: A Randomized Controlled Trial. *Lymphat Res Biol*.  
32 2022;20(2):175-184. doi:10.1089/lrb.2020.0132  
33
- 34 Kwan ML, Cohn JC, Armer JM, Stewart BR, Cormier JN. Exercise in patients with  
35 lymphedema: a systematic review of the contemporary literature. *J Cancer Surviv*.  
36 2011;5(4):320-336  
37
- 38 Lasinski BB, Boris M. Comprehensive lymphedema management: results of a 5 year  
39 follow-up. *Lymphology*. 2002;35(suppl):301-304  
40
- 41 Lasinski BB, McKillip Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, Green JM,  
42 Stewart BR, Cormier JN, Armer JM. A systematic review of the evidence for complete

- 1 decongestive therapy in the treatment of lymphedema from 2004 to 2011. *PM R.*  
2 2012;4(8):580-601
- 3
- 4 Lasinski BB. Complete decongestive therapy for treatment of lymphedema. *Semin Oncol*  
5 *Nurs.* 2013;29(1):20-27
- 6
- 7 Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and  
8 management of a chronic condition in oncologic treatment. *CA Cancer J Clin.*  
9 2009;59(1):8-24
- 10
- 11 Leal NF, Carrara HH, Vieira KF, Ferreira CH. Physiotherapy treatments for breast cancer-  
12 related lymphedema: a literature review. *Rev Latino-Am Enfermagem.*  
13 2009;17(5):730-736
- 14
- 15 Leung EY, Tirlapur SA, Meads C. The management of secondary lower limb  
16 lymphoedema in cancer patients: a systematic review. *Palliat Med.* 2015;29(2):112-  
17 119
- 18
- 19 Lin Y, Yang Y, Zhang X, Li W, Li H, Mu D. Manual Lymphatic Drainage for Breast  
20 Cancer-related Lymphedema: A Systematic Review and Meta-analysis of Randomized  
21 Controlled Trials. *Clin Breast Cancer.* 2022;22(5):e664-e673.  
22 doi:10.1016/j.clbc.2022.01.013
- 23
- 24 Lin Y, Chen Y, Liu R, Cao B. Effect of exercise on rehabilitation of breast cancer surgery  
25 patients: A systematic review and meta-analysis of randomized controlled trials. *Nurs*  
26 *Open.* 2023 Apr;10(4):2030-2043
- 27
- 28 Maccarone MC, Venturini E, Menegatti E, Giancesini S, Masiero S. Water-based exercise  
29 for upper and lower limb lymphedema treatment. *J Vasc Surg Venous Lymphat Disord.*  
30 2023;11(1):201-209. doi:10.1016/j.jvsv.2022.08.002
- 31
- 32 Macdonald JM, Sims N, Mayrovitz HN. Lymphedema, lipedema, and the open wound: the  
33 role of compression therapy. *Surg Clin North Am.* 2003;83(3):639-658.  
34 doi:10.1016/S0039-6109(02)00201-3
- 35
- 36 Marotta N, Lippi L, Ammendolia V, Calafiore D, Inzitari MT, Pinto M, Invernizzi M, de  
37 Sire A. Efficacy of kinesio taping on upper limb volume reduction in patients with  
38 breast cancer-related lymphedema: a systematic review of randomized controlled trials.  
39 *Eur J Phys Rehabil Med.* 2023 Apr;59(2):237-247
- 40
- 41 Martín Jiménez A, Ortega Nieto C, Lista S, et al. Effectiveness of the different components  
42 of complex decongestive therapy in patients with chronic venous insufficiency:

- 1 A systematic review. *Phlebology*. 2025;40(9):651-661.  
 2 doi:10.1177/02683555251333000  
 3
- 4 McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition  
 5 of manual lymph drainage to compression therapy for breast cancer related  
 6 lymphedema: a randomized controlled trial. *Breast Cancer Res Treat*. 2004;86(2):95-  
 7 106  
 8
- 9 McNeely ML, Dolgoy ND, Rafn BS, et al. Nighttime compression supports improved self-  
 10 management of breast cancer-related lymphedema: A multicenter randomized  
 11 controlled trial. *Cancer*. 2022;128(3):587-596. doi:10.1002/cncr.33943  
 12
- 13 McNeely ML, Shallwani SM, Al Onazi MM, Lurie F. The effect of compression therapies  
 14 and therapeutic modalities on lymphedema secondary to cancer: a rapid review and  
 15 evidence map. *Med Oncol*. 2024;41(11):288. Published 2024 Oct 17  
 16
- 17 Megens A, Harris SR. Physical therapist management of lymphedema following treatment  
 18 for breast cancer: a critical review of its effectiveness. *Phys Ther*. 1998;78(12):1302-  
 19 1311  
 20
- 21 Michopoulos E, Papathanasiou G, Vasilopoulos G, Polikandrioti M, Dimakakos E.  
 22 Effectiveness and Safety of Complete Decongestive Therapy of Phase I: A  
 23 Lymphedema Treatment Study in the Greek Population. *Cureus*. 2020 Jul  
 24 19;12(7):e9264. doi: 10.7759/cureus.9264  
 25
- 26 Mondry TE, Riffenburgh RH, Johnstone PA. Prospective trial of complete decongestive  
 27 therapy for upper extremity lymphedema after breast cancer therapy. *Cancer J*.  
 28 2004;10(1):42-49  
 29
- 30 Morris, D et al. “The clinical effects of Kinesio® Tex taping: A systematic  
 31 review.” *Physiotherapy theory and practice* vol. 29,4 (2013): 259-70.  
 32 doi:10.3109/09593985.2012.731675  
 33
- 34 Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies  
 35 for arm lymphoedema secondary to breast cancer treatment. *Ann Oncol*.  
 36 2007;18(4):639-646.  
 37
- 38 National Cancer Institute (NCI). Lymphedema [Physician Data Query (PDQ®)]. Last  
 39 Modified: 2023. Retrieved on March 8, 2026 from  
 40 [http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessio](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)  
 41 [nal/AllPages](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)

- 1 National Lymphedema Network (NLN). Position statement of the national lymphedema  
 2 network. The Diagnosis And Treatment Of Lymphedema. September 2024. Currently  
 3 under review and revision. Retrieved on March 8, 2026 from  
 4 [https://cdn.ymaws.com/lymphnet.org/resource/collection/2EE8AF2F-DE0C-458B-](https://cdn.ymaws.com/lymphnet.org/resource/collection/2EE8AF2F-DE0C-458B-99C0-1B7600362542/WITH_References_-_Lymph_Diagnosis_and_Treatmen.pdf)  
 5 [99C0-1B7600362542/WITH\\_References\\_-\\_Lymph\\_Diagnosis\\_and\\_Treatmen.pdf](https://cdn.ymaws.com/lymphnet.org/resource/collection/2EE8AF2F-DE0C-458B-99C0-1B7600362542/WITH_References_-_Lymph_Diagnosis_and_Treatmen.pdf)  
 6
- 7 National Lymphedema Network (NLN). Position statement of the national lymphedema  
 8 network. Exercise. December 2011. Accessed March 8, 2026 from  
 9 <https://klosetraining.com/wp-content/uploads/2015/05/NLNexercise.pdf>  
 10
- 11 Nelson NL. Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic  
 12 Review. *J Strength Cond Res.* 2016 Sep;30(9):2656-65  
 13
- 14 Oremus M, Walker K, Dayes I, Raina P. Diagnosis and Treatment of Secondary  
 15 Lymphedema. Agency for Healthcare Research and Quality (US); 2010  
 16
- 17 Oremus M, Dayes I, Walker K, Raina P. Systematic review: conservative treatments for  
 18 secondary lymphedema. *BMC Cancer.* 2012;12:6  
 19
- 20 Palmer SJ. An overview of manual lymphatic drainage. *Br J Community Nurs.*  
 21 2024;29(9):438-440  
 22
- 23 Pekyavaş NÖ, Tunay VB, Akbayrak T, Kaya S, Karataş M. Complex decongestive therapy  
 24 and taping for patients with postmastectomy lymphedema: a randomized controlled  
 25 study. *Eur J Oncol Nurs.* 2014;18(6):585-590  
 26
- 27 Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and  
 28 management. *CA Cancer J Clin.* 2000;50(5):292-311  
 29
- 30 Poage E, Singer M, Armer J, Poundall M, Shellabarger MJ. Demystifying lymphedema:  
 31 development of the lymphedema putting evidence into practice card. *Clin J Oncol Nurs.*  
 32 2008;12(6):951-964  
 33
- 34 Qiao J, Yang LN, Kong YH, Huang X, Li Y, Bai DQ. Effect of Manual Lymphatic  
 35 Drainage on Breast Cancer-Related Postmastectomy Lymphedema: A Meta-analysis  
 36 of Randomized Controlled Trials. *Cancer Nurs.* 2023;46(2):159-166.  
 37 doi:10.1097/NCC.0000000000001061  
 38
- 39 Rajaram R, Lee J, Lok E, Ng S, Yamamoto T. The Management of Head and Neck  
 40 Lymphoedema: A 2025 Systematic Review. *Head Neck.* 2025;47(10):2897-2910.  
 41 doi:10.1002/hed.28265

- 1 Rangon FB, da Silva J, Dibai-Filho AV, Guirro RRJ, Guirro ECO. Effects of Complex  
 2 Physical Therapy and Multimodal Approaches on Lymphedema Secondary to Breast  
 3 Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.  
 4 Arch Phys Med Rehabil. 2022;103(2):353-363  
 5
- 6 Ridner SH. Breast cancer lymphedema: pathophysiology and risk reduction guidelines.  
 7 Oncol Nurs Forum. 2002;29(9):1285-1293  
 8
- 9 Ryans K, Perdomo M, Davies CC, Levenhagen K, Gilchrist L. Rehabilitation interventions  
 10 for the management of breast cancer-related lymphedema: developing a patient-  
 11 centered, evidence-based plan of care throughout survivorship. J Cancer Surviv.  
 12 2023;17(1):237-245. doi:10.1007/s11764-021-00991-2  
 13
- 14 Şahinoğlu E, Ergin G, Karadibak D. The agreement between three classification systems  
 15 used to grade the severity of lymphedema in patients with upper and lower extremity  
 16 lymphedema: A retrospective study. Physiother Theory Pract. 2024 Apr;40(4):874-879  
 17
- 18 Saraswathi V, Latha S, Niraimathi K, Vidhubala E. Managing lymphedema, increasing  
 19 range of motion, and quality of life through yoga therapy among breast cancer  
 20 survivors: a systematic review. Int J Yoga. 2021;14(1):3-17  
 21
- 22 Senger JB, Kadle RL, Skoracki RJ. Current Concepts in the Management of Primary  
 23 Lymphedema. Medicina (Kaunas). 2023 May 6;59(5):894  
 24
- 25 Sezgin Ozcan D, Dalyan M, Unsal Delialioglu S, Duzlu U, Polat CS, Koseoglu BF.  
 26 Complex decongestive therapy enhances upper limb functions in patients with breast  
 27 cancer-related lymphedema. Lymphat Res Biol. 2018;16(5):446-452  
 28
- 29 Shahshenas S, Yarmohammadi H, Soltanipur M, Sheikhi Z. Meta-analysis on effects of  
 30 lymphatic drainage techniques in the management of carpal tunnel syndrome. J Orthop  
 31 Surg Res. 2025;20(1):491. Published 2025 May 20. doi:10.1186/s13018-025-05887-w  
 32
- 33 Shao Y, Qi K, Zhou QH, Zhong DS. Intermittent pneumatic compression pump for breast  
 34 cancer-related lymphedema: a systematic review and meta-analysis of randomized  
 35 controlled trials. Oncol Res Treat. 2014;37(4):170-174  
 36
- 37 Smoot B, Chiavola-Larson L, Lee J, Manibusan H, Allen DD. Effect of low-level laser  
 38 therapy on pain and swelling in women with breast cancer-related lymphedema: a  
 39 systematic review and meta-analysis. J Cancer Surviv. 2015;9(2):287-304

- 1 Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P.  
2 Preoperative assessment enables the early diagnosis and successful treatment of  
3 lymphedema. *Cancer*. 2008;112(12):2809-2819  
4
- 5 Szolnoky G, Lakatos B, Keskeny T, Varga E, Varga M, Dobozy A, Kemény L. Intermittent  
6 pneumatic compression acts synergistically with manual lymphatic drainage in  
7 complex decongestive physiotherapy for breast cancer treatment-related lymphedema.  
8 *Lymphology*. 2009;42(4):188-194  
9
- 10 Szuba A, Cooke JP, Yousuf S, Rockson SG. Decongestive lymphatic therapy for patients  
11 with cancer-related or primary lymphedema. *Am J Med*. 2000;109(4):296-300.  
12
- 13 Thompson B, Gaitatzis K, Janse de Jonge X, Blackwell R, Koelmeyer LA. Manual  
14 lymphatic drainage treatment for lymphedema: a systematic review of the literature. *J*  
15 *Cancer Surviv*. 2021;15(2):244-258  
16
- 17 Torgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guidelines Relevant to Diagnosis,  
18 Assessment, and Management of Lymphedema: A Systematic Review. *Adv Wound*  
19 *Care (New Rochelle)*. 2023;12(1):15-27. doi:10.1089/wound.2021.0149  
20
- 21 Torres Lacomba, M., Yuste Sánchez, M. J., Zapico Goñi, A., Prieto Merino, D., Mayoral  
22 del Moral, O., Cerezo Téllez, E., & Minayo Mogollón, E. (2010). Effectiveness of early  
23 physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised,  
24 single blinded, clinical trial. *BMJ (Clinical research ed.)*, 340, b5396  
25
- 26 Torres-Lacomba, M., Navarro-Brazález, B., Prieto-Gómez, V., Ferrandez, J. C., Bouchet,  
27 J. Y., & Romay-Barrero, H. (2020). Effectiveness of four types of bandages and  
28 kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-  
29 blind, clinical trial. *Clinical rehabilitation*, 34(9), 1230–1241.  
30 <https://doi.org/10.1177/0269215520935943>  
31
- 32 Tsai HJ, Hung HC, Yang JL, Huang CS, Tsao JY. Could Kinesio tape replace the bandage  
33 in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot  
34 study. *Support Care Cancer*. 2009;17(11):1353–1360  
35
- 36 Tümkaya MN, Seven M. Interventions for Prevention and Management of Gynecological  
37 Cancer-Related Lower Limb Lymphedema: A Systematic Scoping Review. *Semin*  
38 *Oncol Nurs*. 2025;41(1):151781  
39
- 40 Tunkel RS, Lachmann E. Lymphedema of the limb. An overview of treatment options.  
41 *Postgrad Med*. 1998;104(4):[pagination unavailable]

- 1 Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related  
 2 lymphedema after intensive decongestive physiotherapy. *Breast Cancer Res Treat.*  
 3 2007;101(3):285–290  
 4
- 5 Vignes S, Blanchard M, Arrault M, Porcher R. Intensive complete decongestive  
 6 physiotherapy for cancer-related upper-limb lymphedema: 11 days achieved greater  
 7 volume reduction than 4. *Gynecol Oncol.* 2013;131(1):127–130  
 8
- 9 Wang L, Shi YX, Wang TT, Chen KX, Shang SM. Breast cancer-related lymphoedema  
 10 and resistance exercise: An evidence-based review of guidelines, consensus statements  
 11 and systematic reviews. *J Clin Nurs.* 2023 May;32(9-10):2208-2227  
 12
- 13 Wang L, Liu Y, Zhang W, et al. Effects of resistance training on breast cancer-related arm  
 14 lymphedema: a systematic review and dose-response meta-analysis. *Support Care*  
 15 *Cancer.* 2025;33(5):395. Published 2025 Apr 17. doi:10.1007/s00520-025-09448-z  
 16
- 17 Wang Y, Ge Y, Xing W, et al. The effectiveness and safety of low-level laser therapy on  
 18 breast cancer-related lymphedema: An overview and update of systematic reviews.  
 19 *Lasers Med Sci.* 2022;37(3):1389-1413. doi:10.1007/s10103-021-03446-3  
 20
- 21 Wittenkamp MC, Christensen J, Vinther A, Juhl CB. The effect of exercise in patients with  
 22 lower limb lymphedema: a systematic review. *Acta Oncol.* 2025;64:484-498.  
 23 Published 2025 Mar 31. doi:10.2340/1651-226X.2025.42560  
 24
- 25 Xue T, Zhang L, Zhang D. Exercise-based interventions for postoperative rehabilitation in  
 26 breast cancer patients: A systematic review and meta-analysis of randomized controlled  
 27 trials. *Medicine (Baltimore).* 2025;104(34):e43705.  
 28 doi:10.1097/MD.00000000000043705  
 29
- 30 Watanabe, Y., Koshiyama, M., Seki, K., Nakagawa, M., Ikuta, E., Oowaki, M., &  
 31 Sakamoto, S. I. (2019). Development and Themes of Diagnostic and Treatment  
 32 Procedures for Secondary Leg Lymphedema in Patients with Gynecologic  
 33 Cancers. *Healthcare (Basel, Switzerland),* 7(3), 101.  
 34 <https://doi.org/10.3390/healthcare7030101>  
 35
- 36 Yang FA, Wu PJ, Su YT, Strong PC, Chu YC, Huang CC. Effect of Kinesiology Taping  
 37 on Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis of  
 38 Randomized Controlled Trials. *Clin Breast Cancer.* 2024;24(6):541-551.e1  
 39
- 40 Yeung W, Semciw AI. Aquatic Therapy for People with Lymphedema: A Systematic  
 41 Review and Meta-analysis. *Lymphat Res Biol.* 2018 Feb;16(1):9-19

- 1 Zasadzka E, Trzmiel T, Kleczewska M, Pawlaczyk M. Comparison of the effectiveness of
- 2 complex decongestive therapy and compression bandaging as a method of treatment of
- 3 lymphedema in the elderly. *Clin Interv Aging*. 2018;13:929–934
- 4
- 5 Zuther E, Norton S. Pathology. In: *Lymphedema Management: The Comprehensive Guide*
- 6 *for Practitioners*. 3rd ed. New York, NY: Thieme Medical Publishers; 2013